<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acquired hyperpigmentation disorders</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acquired hyperpigmentation disorders</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acquired hyperpigmentation disorders</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Neelam Vashi, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Roopal V Kundu, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Erik Stratman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 08, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H804749"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Disorders of cutaneous discoloration comprise a large group of skin conditions characterized by an increase of chromophores of melanotic origin (hyperpigmentation) and/or an increase of nonmelanotic chromophores (hyperchromias) [<a href="#rid1">1,2</a>]. Hyperpigmentation is the darkening or increase in the natural color of the skin, usually due to an increased deposition of melanin (hypermelanosis) in the epidermis and/or dermis. Less frequently, it may be caused by the deposition in the dermis of endogenous or exogenous pigments, such as hemosiderin, iron, or heavy metals.</p><p>Hyperpigmentation is a feature of a multitude of clinical conditions, ranging from normal variations of skin color to acquired and inherited syndromes, and is one of the most common reasons for dermatologic consultation, particularly in patients with darkly pigmented skin [<a href="#rid1">1,3-5</a>]. Although hyperpigmentation is not harmful, it can cause significant cosmetic disfigurement and become a persistent psychosocial burden [<a href="#rid6">6</a>] due to the limited efficacy of available treatments.</p><p>This topic will review the approach to acquired hyperpigmentation disorders. Melasma and postinflammatory hyperpigmentation are discussed separately. Congenital and inherited hyperpigmentation disorders are also discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/121155.html" rel="external">"Melasma: Epidemiology, pathogenesis, clinical presentation, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6621.html" rel="external">"Melasma: Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/95847.html" rel="external">"Postinflammatory hyperpigmentation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/111807.html" rel="external">"Congenital and inherited hyperpigmentation disorders"</a>.)</p><p></p><p class="headingAnchor" id="H63304639"><span class="h1">DETERMINANTS OF SKIN COLOR</span><span class="headingEndMark"> — </span>The color of human skin is mainly determined by the two types of melanin: black-brown eumelanin and yellow-red pheomelanin. Other significant determinants are capillary blood flow, chromophores (eg, carotene or lycopene), and the collagen content of the dermis. Eumelanin and pheomelanin are present in individuals of all skin colors, but their ratio is highly variable and determines the hue of the skin [<a href="#rid7">7</a>]. </p><p>Melanin is produced by melanocytes, specialized cells of neural crest origin that reside in the basal layer of the epidermis. The biosynthesis of melanin occurs in lysosome-like organelles called melanosomes, which are transported to the cell periphery and transferred from the dendritic tips of the melanocytes to the surrounding keratinocytes [<a href="#rid8">8</a>]. Each melanocyte is associated with approximately 36 basal keratinocytes to form the so-called epidermal melanin unit. </p><p>Differences in the number, size, and aggregation of melanosomes within the melanocytes and keratinocytes, but not in the overall number of melanocytes, contribute to ethnic differences in skin color [<a href="#rid9">9,10</a>]. Skin that is darkly pigmented has a higher content of melanin, higher eumelanin-to-pheomelanin ratio, nonaggregated and larger melanosomes,<sup> </sup>and slower melanosome degradation within the keratinocytes [<a href="#rid11">11</a>]. </p><p class="headingAnchor" id="H1195732635"><span class="h1">PATHOPHYSIOLOGY OF HYPERPIGMENTATION</span></p><p class="headingAnchor" id="H55789961"><span class="h2">Hypermelanosis</span><span class="headingEndMark"> — </span>Skin hyperpigmentation is, in most cases, caused by increased biosynthesis and deposition of melanin in the epidermis (basal and suprabasal layers) and/or in the dermis [<a href="#rid12">12,13</a>]. These abnormalities may be due to both acquired and genetic factors. </p><p>The normal dermis does not contain melanin. Dermal hypermelanosis may develop through several mechanisms: </p><p class="bulletIndent1"><span class="glyph">●</span>Transfer of melanin from the epidermis to the dermis and accumulation within melanophages ("pigmentary incontinence"). This process is commonly observed in inflammatory skin diseases that involve a damage of the basal layer and/or the dermoepidermal junction. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Production of melanin by ectopic dermal melanocytes. Examples of dermal melanocytosis are the nevus of Ota and nevus of Ito.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Binding of melanin to exogenous pigments deposited in the dermis. </p><p></p><p class="headingAnchor" id="H55790081"><span class="h2">Other pigments</span><span class="headingEndMark"> — </span>Cutaneous hyperpigmentation can be caused by the deposition in the dermis of endogenous or exogenous pigments, such as hemosiderin, iron, or heavy metals. Recurrent extravasation of red blood cells in the dermis leads to deposition of hemosiderin, resulting in a red-brown discoloration of the skin. Dermal hyperpigmentation mimicking dermal hypermelanosis can be caused by topical or systemic exposure to heavy metals (eg, silver, gold, mercury). Some metals, such as iron, may also stimulate melanogenesis, as observed in patients with hemochromatosis.</p><p class="headingAnchor" id="H28520033"><span class="h1">PATIENT EVALUATION AND DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of hyperpigmentation disorders may be challenging. An algorithmic approach to the diagnosis based upon history and clinical parameters is shown in the figure  (<a class="graphic graphic_algorithm graphicRef93949" href="/z/d/graphic/93949.html" rel="external">algorithm 1</a>). In most cases, the initial patient evaluation involves a detailed family and personal medical history and a complete physical examination, which should include a careful search for additional cutaneous and extracutaneous signs and symptoms. </p><p>Questions that may be useful for the evaluation of patients with hyperpigmentation disorders include [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Is the disorder congenital or acquired? </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If not present at birth, was the disorder onset in childhood or adolescence? </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Is the pigmentation localized or diffuse? </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Is the pigmentation well circumscribed or ill defined? </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Does the pigmentation have a pattern (eg, linear, reticular)? </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Is the pigmentation associated with inflammation and/or prior cutaneous injury?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Is the pigmentation stable, progressing, or regressing?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Does the patient have concomitant systemic diseases?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Does the patient have a history of exposure to a new medication?</p><p></p><p class="headingAnchor" id="H5428465"><span class="h2">History</span><span class="headingEndMark"> — </span>A detailed medical history should be obtained from the patient to determine if the hyperpigmentation is related to an underlying disease. The possibility of drug-induced pigmentation must be kept in mind. Patients should also be questioned about smoking habits and occupational and or hobby-related exposure to chemicals that may cause hyperpigmentation.</p><p>The course of the disorder is also a useful parameter in the clinical diagnosis of hyperpigmentation disorders. Inherited disorders of hyperpigmentation are often stable, whereas most acquired forms show progression or regression.</p><p class="headingAnchor" id="H5428471"><span class="h2">Skin examination</span><span class="headingEndMark"> — </span>In all patients with hyperpigmentation disorders, a complete skin examination should be performed under visible light and Wood's light. Important clinical parameters include: </p><p class="bulletIndent1"><span class="glyph">●</span>Extent of the pigmentary abnormality (localized versus diffuse)</p><p class="bulletIndent1"><span class="glyph">●</span>Color hue (shades of brown/black, slate-gray/blue)</p><p class="bulletIndent1"><span class="glyph">●</span>Morphology of individual lesions</p><p class="bulletIndent1"><span class="glyph">●</span>Distribution (eg, sun-exposed areas, areas previously involved by inflammatory processes)</p><p class="bulletIndent1"><span class="glyph">●</span>Pattern (eg, linear, reticular, nonfigurate)</p><p></p><p>A careful search for associated cutaneous and extracutaneous signs and symptoms may provide important clues to the diagnosis, particularly in patients with hyperpigmentation disorders associated with systemic diseases or genetic syndromes. </p><p class="headingAnchor" id="H5428508"><span class="h2">Wood's light examination</span><span class="headingEndMark"> — </span>Wood's light, also known as "black light," is ultraviolet A (UVA) light with a peak emission at 365 nm [<a href="#rid14">14</a>]. The patient is examined in a darkened room with the light source held at 10 to 15 cm from the skin. Wood's light can be helpful in determining whether the pigment deposition is predominantly epidermal, dermal, or mixed. However, its effectiveness is limited in patients with darkly pigmented skin [<a href="#rid15">15,16</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidermal hypermelanosis</strong> – Under natural light, epidermal hypermelanosis appears light brown to dark brown in color. The pigmentation, as well as the contrast between involved and uninvolved skin, is enhanced when viewed under a Wood's lamp. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dermal hypermelanosis</strong> – Under natural light, dermal hypermelanosis has a bluish or ashen gray hue with margins less defined than epidermal hypermelanosis. The pigmentation is not accentuated by the Wood's light. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mixed hypermelanosis</strong> – Mixed hypermelanosis appears light to dark brown under natural light, whereas Wood's light examination will show enhancement in some areas and none in others.</p><p></p><p class="headingAnchor" id="H1018587737"><span class="h2">Dermoscopy</span><span class="headingEndMark"> — </span>Dermoscopy (dermatoscopy) refers to skin examination using surface microscopy. It requires a high-quality magnifying lens and a powerful lighting system, which allows examination of skin structures and patterns. (See  <a class="medical medical_review" href="/z/d/html/13521.html" rel="external">"Overview of dermoscopy"</a>.)</p><p>Dermoscopy is a noninvasive technique that has traditionally been utilized in the assessment of melanocytic lesions. Observational studies have suggested a role for dermoscopy for both the identification and differentiation of pigmentary disorders [<a href="#rid17">17</a>]. Under dermoscopy, certain characteristics of skin lesions can be assessed, such as symmetry versus asymmetry, homogeneity versus heterogeneity, pigment distribution, vascular morphology, and lesion border. Dermoscopy can provide information to identify pigmentary disorders and help assess disease severity and treatment response.</p><p class="headingAnchor" id="H5428586"><span class="h2">Reflectance confocal microscopy</span><span class="headingEndMark"> — </span>In vivo reflectance confocal microscopy is a technique that allows noninvasive imaging of the epidermis and papillary dermis at histologic resolution [<a href="#rid18">18</a>]. The confocal microscope emits a near-infrared light from a diode laser source focused on a microscopic skin target. As this light penetrates cellular structures with different refraction indexes, it is naturally reflected and then captured and recomposed by computer software into a two-dimensional grayscale image [<a href="#rid19">19,20</a>].</p><p>Reflectance confocal microscopy is not widely available and is mainly employed in research settings. However, it is a promising technique to diagnose and/or monitor treatment of hypo- and hyperpigmentation disorders without performing repeated biopsies [<a href="#rid21">21,22</a>].</p><p class="headingAnchor" id="H28520051"><span class="h2">Skin biopsy</span><span class="headingEndMark"> — </span>A skin biopsy for histopathologic evaluation is not routinely performed for the diagnosis of hyperpigmentation disorders. However, it may be necessary when the clinical diagnosis is uncertain or there is suspicion for malignancy. Standard stains (eg, hematoxylin and eosin, Fontana-Masson silver stain) and histochemical techniques (eg, Mart-1, Melan-A) are used to evaluate the number and localization of melanocytes and melanin granules in the epidermis and dermis. The main histopathologic findings in selected hyperpigmentation disorders are summarized in the table  (<a class="graphic graphic_table graphicRef95321" href="/z/d/graphic/95321.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H2625341194"><span class="h1">WHEN TO REFER</span><span class="headingEndMark"> — </span>Patients with persistent or extensive areas of abnormal skin hyperpigmentation that does not follow a common clinical pattern or does not respond to first-line treatments should be referred to a board-certified dermatologist for further evaluation and management.</p><p class="headingAnchor" id="H316236138"><span class="h1">CIRCUMSCRIBED HYPERPIGMENTATION</span></p><p class="headingAnchor" id="H459849806"><span class="h2">Onset in childhood/adolescence</span></p><p class="headingAnchor" id="H312759816"><span class="h3">Ephelides (freckles)</span><span class="headingEndMark"> — </span>Ephelides, or freckles, are small, well-demarcated, hyperpigmented macules usually 2 to 4 mm in diameter that occur most frequently in individuals with red or blond hair and lightly pigmented skin  (<a class="graphic graphic_picture graphicRef93960" href="/z/d/graphic/93960.html" rel="external">picture 1</a>). They can first appear during early childhood on sun-exposed skin and are most numerous on the face, dorsal hands, and upper trunk. Ephelides increase in number, size, and depth of pigmentation during the summer months and are smaller, lighter, and fewer in number in the winter. Melanocortin-1 receptor gene variants play a role in the development of ephelides [<a href="#rid23">23,24</a>].</p><p>Ephelides are benign lesions and have no propensity for malignant transformation<sup> </sup>[<a href="#rid25">25</a>]. Histologically, there is a normal epidermis and normal number of melanocytes with large melanosomes, resembling those seen in patients with darkly pigmented skin.</p><p>Treatment involves the use of sun-protective measures. Additional treatment is for cosmetic purposes only. Topical retinoids and depigmenting agents may lighten lesions to a minimal extent. Pigment-specific lasers and light-based therapy are additional therapeutic modalities [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/z/d/html/13637.html" rel="external">"Laser and light therapy for cutaneous hyperpigmentation", section on 'Ephelides (freckles)'</a>.)</p><p class="headingAnchor" id="H2098290391"><span class="h3">Simple lentigines</span><span class="headingEndMark"> — </span>Simple lentigines (lentigo simplex) are benign pigmented macules that result from increased activity of epidermal melanocytes. Simple lentigines are usually small (&lt;5 mm), darker than ephelides, and appear during childhood. They have a scattered distribution and do not show a predilection for sun-exposed areas. </p><p>Multiple lentigines are a feature of numerous genetic disorders  (<a class="graphic graphic_table graphicRef66428" href="/z/d/graphic/66428.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/5560.html" rel="external">"Benign pigmented skin lesions other than melanocytic nevi (moles)", section on 'Lentigo'</a> and  <a class="medical medical_review" href="/z/d/html/111807.html" rel="external">"Congenital and inherited hyperpigmentation disorders", section on 'Genetic syndromes associated with lentiginosis'</a>.)</p><p class="headingAnchor" id="H2753150889"><span class="h3">Partial unilateral lentiginosis</span><span class="headingEndMark"> — </span>Partial unilateral lentiginosis is a rare disorder characterized by the presence of multiple lentigines arising on normally pigmented skin in a unilateral or segmental pattern [<a href="#rid27">27</a>]. Partial unilateral lentiginosis is an acquired disorder in most cases, with lentigines first appearing during childhood or adolescence [<a href="#rid28">28</a>]. The pigmented macules can occur anywhere on one side of the body and may have a zosteriform distribution. Histologically, there is increased pigmentation of the basal layer, with normal or slightly increased number of melanocytes [<a href="#rid29">29</a>].</p><p>In a minority of cases, partial unilateral lentiginosis may be a manifestation of segmental neurofibromatosis type 1 (NF1), a noninherited mosaic form of NF1, characterized by unilateral neurofibromas and/or café-au-lait macules [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis", section on 'Segmental NF1'</a>.)</p><p>Laser treatment with alexandrite quality-switched (Q-switched) laser or Q-switched neodymium-doped yttrium aluminum garnet (Nd:YAG) laser has been used in a few patients with partial unilateral lentiginosis with good results [<a href="#rid31">31,32</a>].</p><p class="headingAnchor" id="H258256558"><span class="h3">Café-au-lait macules</span><span class="headingEndMark"> — </span>Café-au-lait macules (CALM) present as uniform, light-brown, well-demarcated macules or patches that may be present at birth or become evident later in childhood.</p><p class="headingAnchor" id="H1736355331"><span class="h3">Becker melanosis</span><span class="headingEndMark"> — </span>Becker melanosis, also called Becker nevus, is a benign cutaneous hamartoma usually presenting in adolescents as a unilateral, hyperpigmented macule or slightly elevated plaque located on the shoulder or upper trunk  (<a class="graphic graphic_picture graphicRef94158 graphicRef68895" href="/z/d/graphic/94158.html" rel="external">picture 2A-B</a>). In one-half of the cases, there is an associated hypertrichosis. The diagnosis, differential diagnosis, and management of Becker nevus are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5560.html" rel="external">"Benign pigmented skin lesions other than melanocytic nevi (moles)", section on 'Becker nevus'</a>.)</p><p class="headingAnchor" id="H4087466987"><span class="h3">Erythromelanosis follicularis faciei et colli</span><span class="headingEndMark"> — </span>Erythromelanosis follicularis faciei et colli is a rare clinical variant of keratosis pilaris primarily seen in adolescents and young adults [<a href="#rid33">33</a>]. It presents with a gradually progressive, reddish-brown pigmentation surmounted by small follicular papules  (<a class="graphic graphic_picture graphicRef90772" href="/z/d/graphic/90772.html" rel="external">picture 3</a>) [<a href="#rid34">34</a>]. The pigmentation involves the preauricular areas and extends to the cheeks and sides of the neck. Classic keratosis pilaris lesions are often present on the trunk. (See  <a class="medical medical_review" href="/z/d/html/13663.html" rel="external">"Keratosis pilaris"</a>.)</p><p>There is no effective treatment for erythromelanosis follicularis faciei et colli. Topical retinoids, topical tacalcitol, <a class="drug drug_general" data-topicid="8539" href="/z/d/drug information/8539.html" rel="external">hydroquinone</a>, and laser therapy have been used in a few patients with temporary improvement [<a href="#rid33">33,35,36</a>]. Complete regression is difficult to achieve, and relapse is common.</p><p class="headingAnchor" id="H437803910"><span class="h3">Idiopathic eruptive macular pigmentation</span><span class="headingEndMark"> — </span>Idiopathic eruptive macular pigmentation is an exceedingly rare condition of unknown etiology that presents predominantly in children and adolescents with the eruption of asymptomatic, brown macules on the face, neck, proximal extremities, and trunk [<a href="#rid37">37-39</a>]. Histologically, there is a basal layer hyperpigmentation with dermal melanophages; some specimens may show papillomatosis [<a href="#rid37">37,40</a>]. </p><p>The diagnosis is based upon history and clinical and histopathologic findings. Proposed diagnostic criteria include eruption of brown, nonconfluent, asymptomatic macules involving the trunk, neck, and proximal extremities in children or adolescents; no preceding inflammatory lesions; no recent drug exposure; and histopathologic findings of basal cell layer hyperpigmentation, prominent dermal melanophages without visible basal layer damage or lichenoid inflammatory infiltrate, and normal mast cell count [<a href="#rid37">37,38</a>]. </p><p>Most patients will undergo spontaneous clearance in months to years [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H178091355"><span class="h3">Terra firma-forme dermatosis</span><span class="headingEndMark"> — </span>Terra firma-forme dermatosis is an acquired, idiopathic condition characterized by retention hyperkeratosis, which results in the formation of dirt-like plaques despite normal hygiene. It is relatively common and most often occurs in children [<a href="#rid41">41,42</a>].</p><p>Lesions typically involve the neck, ankle (posterior to the medial or lateral malleolus), and face but may also occur on other body areas  (<a class="graphic graphic_picture graphicRef94427 graphicRef94203" href="/z/d/graphic/94427.html" rel="external">picture 4A-B</a>). Diagnosis and treatment can be achieved by removing lesions with gentle isopropyl alcohol swabbing, with once-a-week application as prophylaxis.</p><p class="headingAnchor" id="H1957988464"><span class="h3">Actinic lichen planus</span><span class="headingEndMark"> — </span>Actinic lichen planus (ALP), also known as lichen planus tropicus, is a rare photodistributed variant of lichen planus most commonly seen in children and young adults from the Middle East, East Africa, or India [<a href="#rid43">43-45</a>]. Its pathogenesis is unknown, but exposure to UV radiation appears to have a precipitating effect. (See  <a class="medical medical_review" href="/z/d/html/5662.html" rel="external">"Lichen planus"</a>.)</p><p>ALP usually presents as melasma-like, hyperpigmented patches or red-brown plaques with an annular configuration [<a href="#rid46">46</a>].<strong> </strong>Lesions are typically photodistributed, involving the forehead, face, neck, and dorsal aspect of upper extremities. Lesions typically appear and are exacerbated during the summer months and may improve spontaneously in winter. </p><p>The diagnosis of ALP is based upon clinical and histologic features. On histology, lesions show the typical findings of lichen planus (eg, vacuolar degeneration of the basal cell layer, dyskeratotic cells, band-like lymphocytic dermal infiltrate) with marked pigmentary incontinence.</p><p>The differential diagnosis of ALP includes discoid lupus erythematosus, polymorphous light eruption, melasma, and granuloma annulare. (See  <a class="medical medical_review" href="/z/d/html/121155.html" rel="external">"Melasma: Epidemiology, pathogenesis, clinical presentation, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus", section on 'Discoid lupus erythematosus'</a> and  <a class="medical medical_review" href="/z/d/html/6623.html" rel="external">"Polymorphous light eruption"</a>.)</p><p>Multiple therapies in combination with sunscreens have been tried in individual patients with ALP with varying outcomes. These include photoprotection, topical and intralesional corticosteroids, antimalarials, <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a>, and cyclosporin [<a href="#rid44">44,47-49</a>]. </p><p class="headingAnchor" id="H1196047855"><span class="h2">Onset in adulthood</span></p><p class="headingAnchor" id="H816925915"><span class="h3">Lentigines</span></p><p class="headingAnchor" id="H1107851782"><span class="h4">Solar lentigines</span><span class="headingEndMark"> — </span>Solar lentigines are tan to dark brown macules, 3 to 20 mm in size, that occur on sun-exposed areas, such as the face  (<a class="graphic graphic_picture graphicRef81287 graphicRef96674" href="/z/d/graphic/81287.html" rel="external">picture 5A-B</a>), dorsal aspect of hands  (<a class="graphic graphic_picture graphicRef61452" href="/z/d/graphic/61452.html" rel="external">picture 6</a>) and forearms, upper chest  (<a class="graphic graphic_picture graphicRef95126" href="/z/d/graphic/95126.html" rel="external">picture 7</a>), and upper back  (<a class="graphic graphic_picture graphicRef86484" href="/z/d/graphic/86484.html" rel="external">picture 8</a>), in response to excessive or chronic sun exposure. In younger individuals, they often appear after an acute sunburn. The differential diagnosis and management of lentigines is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5560.html" rel="external">"Benign pigmented skin lesions other than melanocytic nevi (moles)", section on 'Lentigo'</a>.)</p><p>Other than for cosmetic purposes, treatment of lentigines is unnecessary. Therapeutic options include lightening agents, retinoic acid, <a class="drug drug_general" data-topicid="10296" href="/z/d/drug information/10296.html" rel="external">trichloroacetic acid</a>, cryotherapy, and laser therapy [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/z/d/html/13637.html" rel="external">"Laser and light therapy for cutaneous hyperpigmentation", section on 'Lentigines'</a>.)</p><p class="headingAnchor" id="H893544784"><span class="h4">PUVA lentigines</span><span class="headingEndMark"> — </span>Psoralen plus ultraviolet A (PUVA) lentigines are large, irregularly shaped, darkly pigmented macules arising also in sun-protected areas in patients treated with long-term PUVA phototherapy, particularly in those with light phototypes. Histologically, these macules are characterized by a lentiginous proliferation of large melanocytes with mild atypia [<a href="#rid51">51</a>]. Similar macules have been noted in patients with mycosis fungoides treated with narrowband ultraviolet B (UVB) phototherapy [<a href="#rid52">52</a>]. </p><p class="headingAnchor" id="H767362137"><span class="h4">Cronkhite-Canada syndrome</span><span class="headingEndMark"> — </span>Cronkhite-Canada syndrome is a rare, noninherited disorder characterized by polyposis of the digestive tract associated with variable anomalies of ectodermal tissues, including diffuse, nonscarring alopecia, nail dystrophy  (<a class="graphic graphic_picture graphicRef76442" href="/z/d/graphic/76442.html" rel="external">picture 9</a>), and lentigines of the buccal mucosa, face, hands, and feet [<a href="#rid53">53</a>]. Approximately two-thirds of the patients are of Japanese descent [<a href="#rid54">54</a>]. </p><p>The disease typically manifests in the sixth decade of life. Presenting symptoms include diarrhea, weight loss, nausea, vomiting, hypogeusia, and anorexia. A diffuse polyposis is present throughout the gastrointestinal tract. Complications include protein-losing enteropathy, gastrointestinal bleeding, intussusception, and prolapse.</p><p>Cronkhite-Canada syndrome is a progressive disease with variable course and poor prognosis. Medical treatment has included nutritional support, systemic corticosteroids, conventional immunosuppressant agents, H2-receptor antagonists, and anti-TNF agents [<a href="#rid55">55</a>]. Regardless of therapy, the mortality rate exceeds 50 percent. (See  <a class="medical medical_review" href="/z/d/html/2594.html" rel="external">"Overview of colon polyps", section on 'Cronkhite-Canada syndrome'</a>.) </p><p class="headingAnchor" id="H674999992"><span class="h3">Dermatosis papulosa nigra</span><span class="headingEndMark"> — </span>Dermatosis papulosa nigra (DPN) is a common benign condition characterized by lesions considered a variant of seborrheic keratosis. Lesions present as multiple 1 to 5 mm dark brown to black papules most commonly on the face, neck, and upper back  (<a class="graphic graphic_picture graphicRef100131 graphicRef73398" href="/z/d/graphic/100131.html" rel="external">picture 10A-B</a>). DPN affects 35 to 77 percent of individuals of African descent and can also present in other ethnic groups with darkly pigmented skin. DPN typically present at a younger age compared with seborrheic keratoses and can uncommonly be found in children [<a href="#rid56">56,57</a>].</p><p>The pathogenesis of DPN is unknown. Studies have found mutations in fibroblast growth factor receptor 3 and phosphatidylinositol 3-kinase genes [<a href="#rid58">58</a>]. Since many patients report a family history of DPN, a genetic predisposition is most likely. Histopathologic features include acanthosis, papillomatosis, and increased pigmentation of the epidermis.</p><p>The diagnosis is typically made clinically. However, if the diagnosis is uncertain, a biopsy can be performed to differentiate this entity from viral warts, melanocytic and epidermal nevi, and melanoma. </p><p>DPN is a benign condition requiring no therapy. However, some patients may desire treatment for cosmetic reasons. Treatment modalities include electrodesiccation and curettage, cryotherapy, snip removal (for pedunculated lesions), and laser therapy [<a href="#rid59">59,60</a>]. Lasers used for DPN include long-pulsed 1064 nm Nd:YAG laser, 532 nm diode laser, pulsed dye laser, nonablative 1550 nm fractionated laser, potassium titanyl phosphate (KTP) laser, and carbon dioxide (CO<sub>2</sub>) ablative laser [<a href="#rid61">61-67</a>]. </p><p class="headingAnchor" id="H804857"><span class="h3">Maturational hyperpigmentation</span><span class="headingEndMark"> — </span>Darkening of facial skin tone is frequently seen in older individuals with darkly pigmented skin. Maturational hyperpigmentation or maturational dyschromia are terms that refer to a primary darkening of both mature and sun-exposed skin [<a href="#rid68">68</a>]. The onset is in adulthood and is not associated with prior inflammation or skin injury. The hyperpigmentation generally occurs on the lateral aspects of the face and also dorsal hands and feet as a result of chronic sun exposure  (<a class="graphic graphic_picture graphicRef93724" href="/z/d/graphic/93724.html" rel="external">picture 11</a>). (See  <a class="medical medical_review" href="/z/d/html/15255.html" rel="external">"Photoaging"</a>.) </p><p>The etiopathogenesis of maturational hyperpigmentation remains unclear. Chronic sun exposure is likely implicated; obesity and diabetes have been postulated as predisposing factors [<a href="#rid68">68</a>]. The histologic evaluation of hyperpigmented skin reveals mild to moderate proliferation of melanocytes, minimal to absent dermal inflammation, and some reports of papillomatous epidermal proliferation.</p><p>Maturational hyperpigmentation is a diagnosis of exclusion. It is mostly confused with melasma, postinflammatory hyperpigmentation, or acanthosis nigricans. The differential diagnosis also includes photoallergic dermatitis and exogenous ochronosis. (See <a class="local">'Exogenous ochronosis'</a> below.)</p><p>Treatment includes sun-protective measures and topical skin-lightening agents. (See  <a class="medical medical_review" href="/z/d/html/6621.html" rel="external">"Melasma: Management", section on 'Topical skin-lightening agents'</a>.)</p><p class="headingAnchor" id="H804863"><span class="h3">Periorbital hyperpigmentation</span><span class="headingEndMark"> — </span>Periorbital hyperpigmentation, also called idiopathic cutaneous hyperchromia of the orbital region, periorbital melanosis, dark circles, or infraorbital pigmentation, is a common finding in otherwise healthy individuals [<a href="#rid69">69</a>]. The dyspigmentation around the orbital skin is typically bilateral and of a medium to dark brown color, sometimes extending to the upper nose and glabella regions. It may be present on the upper, lower, or both eyelids. It affects males and females equally and is more common in individuals with darkly pigmented skin [<a href="#rid70">70</a>]. A familial form has also been recognized, with variable clinical expression in different members of the family [<a href="#rid71">71</a>]. In familial cases, the hyperpigmentation usually starts during childhood in the lower eyelids and progresses with age to involve the entire periorbital area.</p><p>The cause of periorbital hyperpigmentation is multifactorial. Contributing factors<sup> </sup>include genetic or constitutional pigmentation; dermal melanocytosis; postinflammatory hyperpigmentation; periorbital edema; excessive subcutaneous vascularity; thin, translucent lower eyelid skin overlying the orbicularis oculi muscle; or a shadow effect due to skin laxity and prominent tear trough [<a href="#rid11">11,69,70</a>].</p><p>Excessive sun exposure, drugs, hormonal causes, and extension of pigmentary demarcation lines may be additional contributing<sup> </sup>factors [<a href="#rid72">72</a>]. Histologically, there is an increase in dermal melanin and hemoglobin [<a href="#rid73">73,74</a>].</p><p>There are no therapies of proven efficacy for periorbital hyperpigmentation. Treatment should be directed to the most apparent etiologic factor (eg, topical lightening agents for postinflammatory hyperpigmentation, soft tissue filler for prominent tear trough). However, topical skin-lightening agents, chemical peels [<a href="#rid75">75</a>], lasers [<a href="#rid76">76-78</a>], autologous fat transplantation, fat grafting with and without blepharoplasty [<a href="#rid79">79,80</a>], and dermal fillers [<a href="#rid81">81</a>] have all been tried, but none have provided long-term satisfactory treatment. (See  <a class="medical medical_review" href="/z/d/html/6621.html" rel="external">"Melasma: Management", section on 'Topical skin-lightening agents'</a> and  <a class="medical medical_review" href="/z/d/html/16532.html" rel="external">"Injectable soft tissue fillers: Overview of clinical use"</a>.)</p><p class="headingAnchor" id="H804869"><span class="h3">Melasma</span><span class="headingEndMark"> — </span>Melasma is an acquired hyperpigmentation of the skin that typically affects the sun-exposed areas of the face, including the centrofacial, malar, and mandibular regions  (<a class="graphic graphic_picture graphicRef64109 graphicRef75884" href="/z/d/graphic/64109.html" rel="external">picture 12A-B</a>). It is most common in female individuals with darkly pigmented skin who live in areas of intense ultraviolet (UV) radiation exposure [<a href="#rid82">82</a>]. The clinical features, diagnosis, and management of melasma are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6621.html" rel="external">"Melasma: Management"</a>.) </p><p class="headingAnchor" id="H2446648146"><span class="h3">Poikiloderma of Civatte</span><span class="headingEndMark"> — </span>Poikiloderma of Civatte is a common disorder characterized by mottled pigmentation (hyper- and hypopigmentation), skin atrophy, and telangiectasias involving the lateral aspect of the face, neck, and V of chest  (<a class="graphic graphic_picture graphicRef81779" href="/z/d/graphic/81779.html" rel="external">picture 13</a>) caused by chronic exposure to UV radiation [<a href="#rid83">83</a>]. The submental area is typically spared. Poikiloderma of Civatte is usually seen in individuals older than 40 years with lightly pigmented skin and is more common in females.</p><p>Histologically, poikiloderma of Civatte is characterized by thinning of the spinous layer, hydropic degeneration of the basal cell layer, solar elastosis in the papillary dermis, presence of melanophages in the papillary dermis, and dilatation of the papillary dermal capillaries [<a href="#rid84">84</a>]. </p><p>Poikiloderma of Civatte has a chronic, progressive, and irreversible course that continues with exposure to UV light. Photoprotection is an essential part of management. Therapies directed at reducing the hyperpigmentation and the telangiectatic component include intense pulsed light [<a href="#rid85">85-88</a>] and nonablative fractional laser. (See  <a class="medical medical_review" href="/z/d/html/13638.html" rel="external">"Laser and light therapy for cutaneous vascular lesions"</a> and  <a class="medical medical_review" href="/z/d/html/13637.html" rel="external">"Laser and light therapy for cutaneous hyperpigmentation"</a>.)</p><p class="headingAnchor" id="H468405659"><span class="h3">Acquired dermal macular hyperpigmentation</span><span class="headingEndMark"> — </span>"Acquired dermal macular hyperpigmentation" is an umbrella term that includes disorders clinically described by variably sized, pigmented macules and patches with histologic evidence of pigment incontinence. These diseases include erythema dyschromicum perstans/ashy dermatosis, lichen planus pigmentosus, Riehl melanosis/pigmented contact dermatitis, and idiopathic eruptive macular pigmentation [<a href="#rid89">89</a>].</p><p class="headingAnchor" id="H1170598121"><span class="h4">Erythema dyschromicum perstans</span><span class="headingEndMark"> — </span>Erythema dyschromicum perstans (EDP), also called "ashy dermatosis" or "dermatosis cenicienta," is an uncommon, slowly progressive dermatosis characterized by hyperpigmented macules of variable size and shape of an ashen-gray color [<a href="#rid90">90</a>].<sup> </sup>Most patients with this disorder are from Latin America. EDP is usually seen in young adults, but it may also occur in children [<a href="#rid91">91</a>].</p><p>The etiology of EDP is unknown. There are isolated reports of EDP associated with exposure to medications (most commonly, benzodiazepines and penicillin), radiographic contrast media, pesticides, endocrinopathies, <em>Trichuris trichiura</em> (whipworm) infestation, and human immunodeficiency virus (HIV) infection [<a href="#rid92">92-94</a>]. However, in most cases, a cause or trigger cannot be identified. <em>HLA-DR4</em> allele may be a risk factor for EDP in Mexican patients [<a href="#rid95">95</a>]. </p><p>Histologic examination of the active border of the lesions shows vacuolar alterations of the basal layer with occasional necrotic keratinocytes and colloid bodies resembling lichen planus [<a href="#rid96">96</a>]. In the papillary dermis, there is a mild to moderate perivascular infiltrate of lymphocytes and histiocytes with melanophages. Based upon these findings, it has been hypothesized that EDP may represent a cell-mediated immune reaction to an ingestant, contact allergen, or microorganism [<a href="#rid46">46,90</a>]. Regardless, a diagnosis of EDP cannot be made based on histologic findings alone.</p><p>EDP presents with slate-gray to blue-brown, oval, circular, or irregularly shaped macules and patches that develop gradually in a symmetric distribution  (<a class="graphic graphic_picture graphicRef86650 graphicRef94393" href="/z/d/graphic/86650.html" rel="external">picture 14A-B</a>). The long axis of the lesions may follow the skin cleavage lines. Early lesions may have a thin, raised, and erythematous border. Lesions typically involve the trunk, but they may spread to the neck, upper extremities, and face. EDP is usually asymptomatic, but mild pruritus may occur. </p><p>EDP is difficult to diagnose. It may share clinical and histologic features with other entities, including lichen planus pigmentosus, lichenoid drug eruption  (<a class="graphic graphic_picture graphicRef59258" href="/z/d/graphic/59258.html" rel="external">picture 15</a>), infectious diseases (eg, leprosy, pinta), and postinflammatory hyperpigmentation. (See  <a class="medical medical_review" href="/z/d/html/5662.html" rel="external">"Lichen planus"</a> and  <a class="medical medical_review" href="/z/d/html/15763.html" rel="external">"Lichenoid drug eruption (drug-induced lichen planus)"</a>.)</p><p>There are no effective therapies for EDP. Topical agents, such as corticosteroids and <a class="drug drug_general" data-topicid="8539" href="/z/d/drug information/8539.html" rel="external">hydroquinone</a>, are usually of limited benefit. Oral corticosteroids, antibiotics (eg, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>), antimalarials, <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a>, <a class="drug drug_general" data-topicid="8502" href="/z/d/drug information/8502.html" rel="external">griseofulvin</a>, and UV light therapy have been tried with variable results. Successful treatment with topical <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> [<a href="#rid97">97</a>], <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> [<a href="#rid98">98</a>], <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a> [<a href="#rid99">99,100</a>], and <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> [<a href="#rid101">101</a>] has been reported in a small number of patients. Sustained resolution with narrowband UVB has been reported in one patient [<a href="#rid102">102</a>].</p><p>The disease is slowly progressive and persistent. Spontaneous resolution over months to years has been reported in children [<a href="#rid103">103</a>].</p><p class="headingAnchor" id="H172542389"><span class="h4">Lichen planus pigmentosus</span><span class="headingEndMark"> — </span>Lichen planus pigmentosus is a chronic and progressive disorder of unknown etiology that occurs predominantly in the third to fifth decade of life. Lichen planus pigmentosus is more prevalent in individuals from India, Latin America, and the Middle East [<a href="#rid104">104</a>]. A variety of oils, such as mustard oil (which contains allyl isothiocyanate, a potential photosensitizer), amla oil, and olive oil, have been suggested as possible inciting agents [<a href="#rid105">105,106</a>]. </p><p>Although traditionally considered a variant of lichen planus, lichen planus pigmentosus is considered by many experts as a separate entity [<a href="#rid89">89</a>]. However, some patients may exhibit concurrent findings of lichen planus [<a href="#rid105">105,107</a>]. (See  <a class="medical medical_review" href="/z/d/html/5662.html" rel="external">"Lichen planus"</a>.)</p><p>There are multiple reports of the coexistence of lichen planus pigmentosus and frontal fibrosing alopecia, illustrating that lichen planus pigmentosus may be the herald sign of this scarring type of hair loss and that both entities may have a pathogenic link [<a href="#rid108">108,109</a>]. (See  <a class="medical medical_review" href="/z/d/html/15680.html" rel="external">"Lichen planopilaris", section on 'Frontal fibrosing alopecia'</a>.)</p><p>Lichen planus pigmentosus typically presents with asymptomatic, oval or irregularly shaped, brown to gray-brown macules and patches in sun-exposed areas, including the forehead, temples, and neck  (<a class="graphic graphic_picture graphicRef94397" href="/z/d/graphic/94397.html" rel="external">picture 16</a>). It may also occur on the trunk and in intertriginous areas (lichen planus pigmentosus inversus) [<a href="#rid89">89</a>]. In contrast with erythema dyschromicum perstans, early lichen planus pigmentosus lesions lack an erythematous border. (See <a class="local">'Erythema dyschromicum perstans'</a> above.). </p><p>The diagnosis of lichen planus pigmentosus is based on clinical and histologic findings. Histopathology shows prominent dermal melanophages with or without features of interface dermatitis. The differential diagnosis includes lichen planus, erythema dyschromicum perstans, melasma, lichenoid drug eruptions, and postinflammatory hyperpigmentation. </p><p>Lichen planus pigmentosus is a chronic, relapsing disorder with exacerbations and remissions. First-line treatment involves the use of sun-protective measures to prevent further darkening. Other treatment options include topical corticosteroids, topical calcineurin inhibitors, skin-lightening agents, oral retinoids, UV light therapy, antimalarials, and laser therapy [<a href="#rid110">110-114</a>]. (See  <a class="medical medical_review" href="/z/d/html/5662.html" rel="external">"Lichen planus", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H1070540886"><span class="h4">Riehl's melanosis (pigmented contact dermatitis)</span><span class="headingEndMark"> — </span>Riehl's melanosis or pigmented contact dermatitis is a dermal melanosis involving the face and neck caused by repeated contact with cosmetic ingredients [<a href="#rid115">115</a>]. A mild erythema and pruritus typically precede the development of a diffuse or reticulated hyperpigmentation  (<a class="graphic graphic_picture graphicRef89290" href="/z/d/graphic/89290.html" rel="external">picture 17</a>). The involved skin appears brown, brown-gray, or blue-gray, depending upon the causal agent, depth of pigment deposition, and background skin color. </p><p>Histologically, there is vacuolar degeneration of the basal layer of the epidermis resulting in pigment incontinence in the dermis [<a href="#rid116">116</a>]. The papillary dermis contains an infiltrate of lymphocytes and macrophages containing large amounts of melanin.</p><p>The diagnosis is based upon the clinical appearance and history of cosmetic use. Patch testing to standard series, cosmetic series, fragrance series, and additional ingredients found in patients' personal products may be helpful in identifying the offending agent. Photopatch testing may be useful in some patients. When results are equivocal or negative, provocative use test or repeated open application test (ROAT) can be administered<sup> </sup>[<a href="#rid73">73</a>]. (See  <a class="medical medical_review" href="/z/d/html/16691.html" rel="external">"Patch testing"</a>.)</p><p>The differential diagnosis includes melasma, nevus of Hori, photosensitivity reactions, and berloque dermatitis (phytophotodermatitis). (See  <a class="medical medical_review" href="/z/d/html/6621.html" rel="external">"Melasma: Management"</a> and  <a class="medical medical_review" href="/z/d/html/13655.html" rel="external">"Clinical features and diagnosis of allergic contact dermatitis"</a>.)</p><p>Treatment involves complete avoidance of the suspected allergen. Sun-protective measures, skin-lightening agents, and chemical peels can accelerate the resolution of pigmentation changes. </p><p class="headingAnchor" id="H657960352"><span class="h4">Idiopathic eruptive macular pigmentation</span><span class="headingEndMark"> — </span>(See <a class="local">'Idiopathic eruptive macular pigmentation'</a> above.)</p><p class="headingAnchor" id="H3293687327"><span class="h3">Erythrose péribuccale pigmentaire de Brocq</span><span class="headingEndMark"> — </span>A rare form of facial hyperpigmentation and probably a variant of Riehl's melanosis is the so-called "erythrose péribuccale pigmentaire de Brocq" or "erythrosis pigmentosa mediofacialis." It is characterized by diffuse, symmetric, red-brown pigmentation around the mouth with sparing of the vermillion border [<a href="#rid34">34</a>]. It may extend to the forehead, temples, and angles of the jaw. </p><p>Histologic examination shows orthokeratotic hyperkeratosis, no specific inflammatory epidermal reaction pattern, and pigment incontinence with melanophages in the upper dermis. Enlarged follicular openings containing keratin plugs and often <em>Demodex folliculorum</em> have also been noted [<a href="#rid117">117,118</a>]. </p><p>The pigmentation tends to be persistent. Treatment is difficult and involves sun avoidance and the use of skin-lightening agents [<a href="#rid119">119</a>].</p><p class="headingAnchor" id="H3959661041"><span class="h3">Nevus of Hori</span><span class="headingEndMark"> — </span>Acquired bilateral nevus of Ota-like macules, or nevus of Hori, is a common, dermal, melanocytic hyperpigmentation seen in some Asian populations, primarily in young and middle-aged Chinese and Japanese females [<a href="#rid120">120-122</a>]. It is characterized by blue-gray to gray-brown macules, primarily on the zygoma and less often on the forehead, temples, upper eyelids, and root and alae of the nose. </p><p>Although nevus of Hori shares histologic similarities with nevus of Ota, it can be clinically distinguished from nevus of Ota by late onset in adulthood, bilateral presentation, speckled or confluent distribution, and lack of ocular and mucosal involvement. The differential diagnosis includes melasma, lentigines, and ephelides. (See  <a class="medical medical_review" href="/z/d/html/6621.html" rel="external">"Melasma: Management"</a> and  <a class="medical medical_review" href="/z/d/html/5560.html" rel="external">"Benign pigmented skin lesions other than melanocytic nevi (moles)"</a>.)</p><p>Laser therapy alone or in combination with chemical peels is the major treatment modality for nevus of Hori [<a href="#rid121">121</a>]. Pigment-selective lasers and their combinations (eg, 532 nm Q-switched Nd:YAG laser followed by a 1064 nm Q-switched Nd:YAG laser, or scanned CO<sub>2</sub> laser or intense pulsed light with a Q-switched ruby laser) have been successfully used in small series [<a href="#rid123">123-127</a>]. Adverse effects of treatment include postinflammatory hypo- and hyperpigmentation. (See  <a class="medical medical_review" href="/z/d/html/13637.html" rel="external">"Laser and light therapy for cutaneous hyperpigmentation"</a>.)</p><p class="headingAnchor" id="H1956669585"><span class="h3">Atrophoderma of Pasini and Pierini</span><span class="headingEndMark"> — </span>Atrophoderma of Pasini and Pierini is a rare disorder of unknown etiology presenting with single or multiple oval-shaped, well-demarcated areas of skin that appear depressed and hyperpigmented  (<a class="graphic graphic_picture graphicRef109166 graphicRef109162" href="/z/d/graphic/109166.html" rel="external">picture 18A-B</a>). The diagnosis, differential diagnosis, and treatment of atrophoderma of Pasini and Pierini are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/108709.html" rel="external">"Atrophoderma of Pasini and Pierini"</a>.)</p><p class="headingAnchor" id="H327031723"><span class="h3">Acquired brachial cutaneous dyschromatosis</span><span class="headingEndMark"> — </span>Acquired brachial cutaneous dyschromatosis is a pigmentary disorder presenting in older individuals, predominantly in females, with large, geographic, gray-brown patches localized to the forearms, usually in a bilateral distribution [<a href="#rid128">128</a>]. The differential diagnosis includes extrafacial melasma. The presence of hypopigmented macules and the absence of characteristic facial melasma lesions and any relation to estrogens, pregnancy, or hormone replacement therapy can help distinguish acquired brachial cutaneous dyschromatosis from melasma. </p><p>On histology, the hyperpigmented patches are characterized by poikilodermatous changes, including epidermal atrophy, increased basal layer pigmentation, solar elastosis, and telangiectasias. Based upon the histologic similarity with poikiloderma of Civatte, acquired brachial cutaneous dyschromatosis is thought to be a manifestation of chronic sun damage [<a href="#rid129">129</a>].</p><p class="headingAnchor" id="H316236245"><span class="h3">Exogenous ochronosis</span><span class="headingEndMark"> — </span>Exogenous ochronosis is a rare condition resulting from the deposition of homogentisic acid in the dermis following a prolonged exposure to a variety of topical products used in skin-lightening agents, such as <a class="drug drug_general" data-topicid="8539" href="/z/d/drug information/8539.html" rel="external">hydroquinone</a>, resorcinol, phenol, mercury, and picric acid [<a href="#rid130">130,131</a>]. The highest incidence is reported in African countries, due to the widespread use of these agents [<a href="#rid132">132,133</a>]. (See  <a class="medical medical_review" href="/z/d/html/110148.html" rel="external">"Topical skin-lightening agents: Complications of use in the nonmedical setting", section on 'Exogenous ochronosis'</a>.)</p><p>Exogenous ochronosis presents as an asymptomatic, localized, symmetric, blue-gray discoloration of the skin with characteristic hyperchromic, pinpoint, caviar-like papules in photo-exposed regions (eg, face, sides and back of the neck, back, and extensor surfaces of limbs  (<a class="graphic graphic_picture graphicRef90021 graphicRef111604" href="/z/d/graphic/90021.html" rel="external">picture 19A-B</a>)). There is often an erythematous, pinkish hue of the skin underlying and surrounding the hyperchromic papules.</p><p>The diagnosis is made by careful history taking but often requires a skin biopsy, since exogenous ochronosis can be easily confused with postinflammatory hyperpigmentation, melasma, and pigmented contact dermatitis (Riehl's melanosis). Histology shows a microscopic deposition of ochre-colored pigment in the papillary dermis, resembling the endogenous ochronosis associated with alkaptonuria [<a href="#rid134">134</a>].</p><p>There is no effective treatment for exogenous ochronosis. Foremost, the offending medication should be stopped. Topical agents, dermabrasion, CO<sub>2</sub> laser, chemical peels, Q-switched Nd:YAG laser, Q-switched alexandrite laser, and fractional CO<sub>2</sub> laser have been used in a small number of patients with inconsistent results [<a href="#rid130">130,135-140</a>].</p><p class="headingAnchor" id="H1378742282"><span class="h3">Hyperpigmentation of the oral mucosa</span></p><p class="headingAnchor" id="H1095908601"><span class="h4">Physiologic hyperpigmentation</span><span class="headingEndMark"> — </span>Physiologic hyperpigmentation of the oral cavity occurs frequently in individuals with darkly pigmented skin, is asymptomatic, and does not require treatment. Oral pigmentation can be found along the lower vermillion border, tongue, oral mucosa, palate, and commonly along the attached gingiva.</p><p class="headingAnchor" id="H3751517251"><span class="h4">Oral melanotic macule</span><span class="headingEndMark"> — </span>Oral melanotic macules are small, well-circumscribed, brown-to-black macules commonly occurring on the vermilion border of the lower lip  (<a class="graphic graphic_picture graphicRef112647" href="/z/d/graphic/112647.html" rel="external">picture 20</a>) or on the oral mucosa, more often on the gingiva  (<a class="graphic graphic_picture graphicRef112648" href="/z/d/graphic/112648.html" rel="external">picture 21</a>) and hard palate  (<a class="graphic graphic_picture graphicRef112649" href="/z/d/graphic/112649.html" rel="external">picture 22</a>). They range in size from a few millimeters to more than one centimeter, are often solitary but can be multiple, and are frequently seen in individuals with darkly pigmented skin. (See  <a class="medical medical_review" href="/z/d/html/5572.html" rel="external">"Oral lesions", section on 'Oral melanotic macules'</a>.)</p><p>A biopsy may be required to rule out mucosal melanoma. Histologically, melanotic macules show an increased deposition of melanin without increase in the number of basal melanocytes. Melanin pigment is also observed in melanophages in the upper portion of the lamina propria. </p><p class="headingAnchor" id="H3908165276"><span class="h4">Oral mucosal melanoma</span><span class="headingEndMark"> — </span>Mucosal melanoma is a rare, aggressive malignancy that carries a very poor prognosis [<a href="#rid141">141</a>]. It typically presents as an asymptomatic, brown to black macule or patch located in the maxillary gingival or palatal mucosa  (<a class="graphic graphic_picture graphicRef118923" href="/z/d/graphic/118923.html" rel="external">picture 23</a>). Lesions often have irregular borders and may be ulcerated. Biopsy is required for diagnosis. (See  <a class="medical medical_review" href="/z/d/html/5572.html" rel="external">"Oral lesions", section on 'Melanoma'</a>.)</p><p class="headingAnchor" id="H2995432061"><span class="h4">Laugier-Hunziker syndrome</span><span class="headingEndMark"> — </span>Laugier-Hunziker syndrome (also called idiopathic lenticular mucocutaneous pigmentation) is an acquired, benign disorder presenting in adults with lentigines on the lips and buccal mucosa  (<a class="graphic graphic_picture graphicRef94244" href="/z/d/graphic/94244.html" rel="external">picture 24</a>). Approximately one-half of the patients also have longitudinal melanonychia and macular pigmentation of the genitals [<a href="#rid142">142</a>] (see  <a class="medical medical_review" href="/z/d/html/121519.html" rel="external">"Longitudinal melanonychia"</a>). Palms and soles are frequently involved. There are no underlying systemic abnormalities and no malignant predisposition. </p><p>The diagnosis of Laugier-Hunziker syndrome is one of exclusion and is usually made after ruling out other causes of oral and labial hyperpigmentation, including: </p><p class="bulletIndent1"><span class="glyph">●</span>Physiologic pigmentation seen in patients with darkly pigmented skin </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inherited diseases associated with lentiginosis (eg, Peutz-Jeghers syndrome, LEOPARD [<strong>l</strong>entigines, <strong>e</strong>lectrocardiogram conduction abnormalities, <strong>o</strong>cular hypertelorism, <strong>p</strong>ulmonic stenosis, <strong>a</strong>bnormal genitalia, <strong>r</strong>etardation of growth, and sensorineural <strong>d</strong>eafness] syndrome, Carney complex) (see  <a class="medical medical_review" href="/z/d/html/2533.html" rel="external">"Peutz-Jeghers syndrome: Clinical manifestations, diagnosis, and management"</a> and  <a class="medical medical_review" href="/z/d/html/111807.html" rel="external">"Congenital and inherited hyperpigmentation disorders", section on 'LEOPARD syndrome'</a> and  <a class="medical medical_review" href="/z/d/html/100662.html" rel="external">"Carney complex"</a>) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cronkhite-Canada syndrome (see <a class="local">'Cronkhite-Canada syndrome'</a> above) </p><p></p><p>The absence of systemic symptoms, such as fatigue, weight loss, cardiovascular or gastrointestinal disorders, and negative findings in upper gastrointestinal endoscopy and colonoscopy support the diagnosis of Laugier-Hunziker syndrome. (See  <a class="medical medical_review" href="/z/d/html/111807.html" rel="external">"Congenital and inherited hyperpigmentation disorders", section on 'Genetic syndromes associated with lentiginosis'</a>.)</p><p>No treatment is necessary. However, some patients may require the removal of pigmented lesions for cosmetic reasons. Cryosurgery, Nd:YAG lasers, and the Q-switched alexandrite laser have been used in single case reports [<a href="#rid143">143-145</a>]. (See  <a class="medical medical_review" href="/z/d/html/13637.html" rel="external">"Laser and light therapy for cutaneous hyperpigmentation", section on 'Lentigines'</a>.)</p><p class="headingAnchor" id="H193502596"><span class="h4">Smoker's melanosis</span><span class="headingEndMark"> — </span>Smoker's melanosis is characterized by irregular macular hyperpigmentation of the oral mucosa secondary to tobacco smoking [<a href="#rid146">146-148</a>]. It may be due to the stimulating effect of nicotine on the melanocytes located in the basal layer of the oral mucosa. (See  <a class="medical medical_review" href="/z/d/html/5572.html" rel="external">"Oral lesions", section on 'Smoker's melanosis'</a>.)</p><p>Lesions consist of brown patches most commonly located on the mandibular anterior gingiva in cigarette smokers and buccal mucosa in pipe smokers [<a href="#rid147">147</a>]. In those who engage in reverse smoking (smoking from the lit end), pigmentation changes are most common on the hard palate. </p><p>The diagnosis is usually clinical. However, a biopsy for histopathologic examination may be warranted if the diagnosis is unclear or the lesion is suspicious for malignancy. The differential diagnosis includes physiologic pigmentation (mucosal melanosis) in patients with darkly pigmented skin, amalgam tattoo, drug-induced hyperpigmentation, Addison disease, melanoacanthoma, and mucosal melanoma. (See  <a class="medical medical_review" href="/z/d/html/5572.html" rel="external">"Oral lesions", section on 'Pigmented lesions'</a>.)</p><p>There are no treatments for smoker's melanosis. Lesions tend to resolve spontaneously over a period of several years of smoking discontinuation [<a href="#rid149">149</a>].</p><p class="headingAnchor" id="H79111161"><span class="h1">PATTERNED HYPERPIGMENTATION</span></p><p class="headingAnchor" id="H2716913006"><span class="h2">Linear pattern</span></p><p class="headingAnchor" id="H3188786706"><span class="h3">Phytophotodermatitis</span><span class="headingEndMark"> — </span>Phytophotodermatitis is a phototoxic reaction to contact with plants containing furocoumarins  (<a class="graphic graphic_table graphicRef75581" href="/z/d/graphic/75581.html" rel="external">table 3</a>). Patients with phytophotodermatitis typically present with erythema, edema, and bullae in linear, streaked, or splashed configurations on sun-exposed skin that reflect the exposure pattern of the causal furocoumarin. Some patients do not experience the acute inflammatory phase and only present with bizarre, unexplained pigmentation patterns in areas of exposed skin. The acute lesions typically heal leaving linear hyperpigmented lesions  (<a class="graphic graphic_picture graphicRef90428 graphicRef112659" href="/z/d/graphic/90428.html" rel="external">picture 25A-B</a>). (See  <a class="medical medical_review" href="/z/d/html/6622.html" rel="external">"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment", section on 'Phytophotodermatitis'</a>.)</p><p class="headingAnchor" id="H42492127"><span class="h3">Drug-induced linear hyperpigmentation</span></p><p class="headingAnchor" id="H827329867"><span class="h4">Serpentine supravenous hyperpigmentation</span><span class="headingEndMark"> — </span>Serpentine supravenous hyperpigmentation describes a pigmentary pattern that follows the course of an underlying vein proximal to an infusion site [<a href="#rid150">150</a>]. This phenomenon can be caused by a variety of chemotherapy agents, such as <a class="drug drug_general" data-topicid="10046" href="/z/d/drug information/10046.html" rel="external">vinorelbine</a>, <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>, <a class="drug drug_general" data-topicid="9326" href="/z/d/drug information/9326.html" rel="external">daunorubicin</a>, and topical <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a>, but is most commonly associated with topical fluorouracil infusions  (<a class="graphic graphic_table graphicRef94552" href="/z/d/graphic/94552.html" rel="external">table 4</a>) [<a href="#rid151">151,152</a>]. (See  <a class="medical medical_review" href="/z/d/html/2090.html" rel="external">"Cutaneous adverse effects of conventional chemotherapy agents", section on 'Patterned hyperpigmentation (serpentine, flagellate, reticular)'</a>.)</p><p class="headingAnchor" id="H3908234155"><span class="h4">Flagellate hyperpigmentation</span><span class="headingEndMark"> — </span>Flagellate hyperpigmentation, also called flagellate erythema, is a characteristic cutaneous reaction to treatment with <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a> [<a href="#rid153">153,154</a>]. Multiple linear, erythematous or hyperpigmented streaks appear arising at sites of scratching or other minor traumas to the skin  (<a class="graphic graphic_picture graphicRef112661" href="/z/d/graphic/112661.html" rel="external">picture 26</a>). Generalized pruritus is common and may precede the eruption. Histology shows hyperkeratosis, epidermal spongiosis, lymphocyte exocytosis, increased melanin in the basal layer, dermal edema, and perivascular lymphocytic infiltrate. (See  <a class="medical medical_review" href="/z/d/html/2090.html" rel="external">"Cutaneous adverse effects of conventional chemotherapy agents", section on 'Patterned hyperpigmentation (serpentine, flagellate, reticular)'</a>.)</p><p class="headingAnchor" id="H299894960"><span class="h2">Reticulate pattern</span></p><p class="headingAnchor" id="H2929832261"><span class="h3">Drug-induced reticulate hyperpigmentation</span><span class="headingEndMark"> — </span>A reticulate hyperpigmentation is an uncommon side effect of several drugs, most often chemotherapy agents such as <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a>, <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">cytarabine</a>, topical <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a>, and <a class="drug drug_general" data-topicid="8549" href="/z/d/drug information/8549.html" rel="external">idarubicin</a> [<a href="#rid155">155,156</a>]. <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">Diltiazem</a> and topical <a class="drug drug_general" data-topicid="8811" href="/z/d/drug information/8811.html" rel="external">benzoyl peroxide</a> have also been reported as a cause. Diffuse reticulate hyperpigmentation develops predominantly on the trunk and lower extremities. Pruritus is often an accompanying symptom. Histologically, lesions show increased melanin in the basal layer of the epidermis and presence of melanophages in the dermis. The pigmentation tends to slowly resolve after discontinuation of the offending drug. (See  <a class="medical medical_review" href="/z/d/html/2090.html" rel="external">"Cutaneous adverse effects of conventional chemotherapy agents", section on 'Patterned hyperpigmentation (serpentine, flagellate, reticular)'</a>.)</p><p class="headingAnchor" id="H777911091"><span class="h3">Erythema ab igne</span><span class="headingEndMark"> — </span>Erythema ab igne is a reticular, erythematous, pigmented dermatosis seen predominantly in adults resulting from repeated exposures to moderate heat or infrared radiation. Once common among people who sat near open fires or stoves, it is infrequently seen after the introduction of central heating [<a href="#rid157">157</a>]. However, it is still seen in relation to occupational exposure to heat sources (foundry workers, bakers), use of hot water bottles, heating pads or blankets  (<a class="graphic graphic_picture graphicRef72011 graphicRef94428 graphicRef52027" href="/z/d/graphic/72011.html" rel="external">picture 27A-C</a>), heated car seats, and among laptop users who hold computers on their thighs [<a href="#rid158">158-162</a>].</p><p>Erythema ab igne can occur at any site, more often in an asymmetrical distribution, and is usually asymptomatic. The early skin changes usually clear spontaneously in several weeks to months, after the removal of the heat source from the skin [<a href="#rid163">163</a>]. However, longstanding lesions may be associated with permanent hyperpigmentation  (<a class="graphic graphic_picture graphicRef94428 graphicRef72011 graphicRef52027" href="/z/d/graphic/94428.html" rel="external">picture 27A-C</a>).</p><p class="headingAnchor" id="H2301103815"><span class="h3">Confluent and reticulated papillomatosis</span><span class="headingEndMark"> — </span>Confluent and reticulated papillomatosis (CARP) of Gougerot and Carteaud is an uncommon dermatosis characterized by hyperpigmented, scaly macules or papillomatous papules coalescing into confluent patches or plaques centrally and exhibiting a reticular pattern peripherally  (<a class="graphic graphic_picture graphicRef105408 graphicRef76296" href="/z/d/graphic/105408.html" rel="external">picture 28A-B</a>). It occurs in young adults and is usually persistent if left untreated. The pathogenesis, clinical presentation, diagnosis, and treatment of CARP are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/101429.html" rel="external">"Confluent and reticulated papillomatosis"</a>.) </p><p class="headingAnchor" id="H1408504870"><span class="h3">Prurigo pigmentosa</span><span class="headingEndMark"> — </span>Prurigo pigmentosa (PP; also called Nagashima disease and "keto rash") is a rare inflammatory skin disorder characterized by chronic, recurrent, pruritic skin lesions that leave a postinflammatory reticular hyperpigmentation [<a href="#rid164">164,165</a>]. Although PP has been reported most frequently in individuals from East Asia, it has been described in Europe, Australia, North America, and Middle East [<a href="#rid166">166,167</a>]. In a review of 369 cases, the mean age at onset was 26 years (range 13 to 72), with a female predominance (72 percent [<a href="#rid167">167</a>]).</p><p>The cause of PP is unknown. Risk factors include diabetic ketoacidosis, diet with carbohydrate restriction ("ketogenic diet"), fasting, cloth friction, and contact sensitization to metals.</p><p>PP presents with erythematous urticarial papules arranged in a reticular pattern that evolve to crusted papules, papulovesicles and vesicles and finally to a reticulate hyperpigmentation. Predilection sites are the chest, back, and neck in symmetrical distribution [<a href="#rid165">165,168</a>].</p><p>Histopathological features of PP are nonspecific and include mild spongiosis and a dermal inflammatory infiltrate with infiltrate of lymphocytes and neutrophils [<a href="#rid165">165</a>]. Immunohistochemistry shows a dermal infiltrate of T cells predominantly expressing a T cytotoxic phenotype (CD8<sup>+</sup>/CD4<sup>-</sup>) with intraepidermal lymphocytic exocytosis. Intraepidermal neutrophils and isolated necrotic keratinocytes can also be seen.</p><p>The diagnosis of PP is based on careful history, clinical presentation, and histopathologic findings. The differential diagnosis of PP includes pigmented contact dermatitis, confluent reticulated papillomatosis, and Dowling-Degos disease.</p><p>Treatment of PP includes diet modification in patients presenting with ketosis and oral tetracyclines.</p><p>In a systematic review that included 343 patients with PP for whom information on treatment was available, 38 percent received <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> or <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, with complete resolution in approximatively 50 percent of patients; the average time to resolution was 34 days for minocycline and 23 days for doxycycline [<a href="#rid167">167</a>]. Recurrence was reported in 10 percent of patients after stopping treatment.</p><p class="headingAnchor" id="H1801267515"><span class="h1">DIFFUSE NONPATTERNED HYPERPIGMENTATION</span></p><p class="headingAnchor" id="H2157338347"><span class="h2">Drug-induced</span><span class="headingEndMark"> — </span>A wide variety of drugs and chemicals can lead to diffuse cutaneous hyperpigmentation [<a href="#rid169">169-171</a>]. An increased production of melanin and/or the deposition of drug complexes or metals in the dermis are responsible for the skin discoloration. </p><p>The drugs most often causing hyperpigmentation and associated clinical features are summarized in the table  (<a class="graphic graphic_table graphicRef94552" href="/z/d/graphic/94552.html" rel="external">table 4</a>). The hyperpigmentation usually resolves with discontinuation of the offending agent, but the course may be prolonged over months to years.</p><p class="headingAnchor" id="H28520775"><span class="h2">Associated with endocrine, metabolic, and autoimmune diseases</span></p><p class="headingAnchor" id="H28520781"><span class="h3">Addison disease</span><span class="headingEndMark"> — </span>Addison disease (primary adrenal insufficiency) is a clinical syndrome caused by glucocorticoid, mineralocorticoid, and in females, androgen deficiency [<a href="#rid172">172</a>]. Signs and symptoms of chronic adrenal insufficiency include malaise, fatigue, hypotension, anorexia, weight loss, and hyperpigmentation. (See  <a class="medical medical_review" href="/z/d/html/159.html" rel="external">"Clinical manifestations of adrenal insufficiency in adults"</a>.)</p><p>The diffuse hyperpigmentation of Addison disease is caused by the melanocyte stimulating hormone (MSH)-like effect of elevated plasma levels of adrenocorticotropic hormone (ACTH). The pigmentation is typically diffuse, with accentuation in sun-exposed areas, flexures, palmar and plantar creases, and areas of pressure or friction  (<a class="graphic graphic_picture graphicRef74922" href="/z/d/graphic/74922.html" rel="external">picture 29</a>).</p><p>Normally hyperpigmented skin areas, such as the nipples and genitals, become darker. The buccal, conjunctival, and genital mucosa may also be involved  (<a class="graphic graphic_picture graphicRef67179" href="/z/d/graphic/67179.html" rel="external">picture 30</a>). The nails and hair may also darken  (<a class="graphic graphic_picture graphicRef57205" href="/z/d/graphic/57205.html" rel="external">picture 31</a>). (See  <a class="medical medical_review" href="/z/d/html/159.html" rel="external">"Clinical manifestations of adrenal insufficiency in adults", section on 'Hyperpigmentation'</a>.)</p><p>The evaluation of suspected Addison disease involves the measurement of basal serum cortisol and plasma ACTH. The finding of low basal cortisol and elevated plasma ACTH is diagnostic of primary adrenocortical insufficiency. (See  <a class="medical medical_review" href="/z/d/html/154.html" rel="external">"Determining the etiology of adrenal insufficiency in adults"</a>.)</p><p>The hyperpigmentation usually fades after a few months of adequate glucocorticoid therapy, due to cornification and desquamation of hyperpigmented basal keratinocytes. Fading of hair and nails takes longer because the pigmented part of the hair shaft and nail grows out slowly. </p><p class="headingAnchor" id="H60651252"><span class="h3">Diabetic dermopathy</span><span class="headingEndMark"> — </span>Diabetic dermopathy, also called shin spots or pigmented pretibial patches, occurs in approximately one-half of diabetic patients, most often in patients with microangiopathic complications [<a href="#rid173">173,174</a>]. </p><p>It presents with multiple asymptomatic, round, dull red to pink papules or plaques predominantly located on the pretibial skin. Lesions evolve in one to two weeks to well-circumscribed, atrophic, brown macules and patches, often with fine scale  (<a class="graphic graphic_picture graphicRef94248" href="/z/d/graphic/94248.html" rel="external">picture 32</a>). </p><p>The diagnosis of diabetic dermopathy is clinical. A skin biopsy is not routinely done. If performed, it shows nonspecific findings, including edema of the epidermis and papillary dermis, red blood cell extravasation, and a mild perivascular lymphohistiocytic infiltrate [<a href="#rid173">173</a>]. Older lesions show epidermal atrophy and scattered hemosiderin deposits. </p><p>There is no treatment for diabetic dermopathy. The lesions may resolve spontaneously over time or persist indefinitely.</p><p class="headingAnchor" id="H79111295"><span class="h3">Acanthosis nigricans</span><span class="headingEndMark"> — </span>Acanthosis nigricans is a common disorder characterized by hyperchromic, velvety plaques located in intertriginous areas such as the axillae, groin, posterior neck  (<a class="graphic graphic_picture graphicRef94426" href="/z/d/graphic/94426.html" rel="external">picture 33</a>), and, less commonly, the face. Histologically, it is characterized by hyperkeratosis, epidermal papillomatosis, and slight, variable acanthosis, with normal melanocyte density [<a href="#rid173">173</a>]. There is no melanin deposition, and the darkening is mainly due to hyperkeratosis. </p><p>Acanthosis nigricans occurs in approximately 40 percent of patients with diabetes mellitus type 2. However, it may also occur in other endocrine and metabolic disorders, most of which are associated with insulin resistance. Rarely, acanthosis nigricans may be a paraneoplastic syndrome.</p><p>The etiology, clinical manifestations, diagnosis, and treatment of acanthosis nigricans are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/13754.html" rel="external">"Acanthosis nigricans"</a>.) </p><p class="headingAnchor" id="H28521927"><span class="h3">Hyperthyroidism</span><span class="headingEndMark"> — </span>Cutaneous changes associated with thyrotoxicosis include a localized or generalized hyperpigmentation with a distribution similar to that seen in Addison disease (eg, creases of palms and soles, buccal mucosa). The hyperpigmentation is thought to be caused by increased release of pituitary ACTH in response to increased cortisol degradation [<a href="#rid175">175</a>]. (See  <a class="medical medical_review" href="/z/d/html/7833.html" rel="external">"Overview of the clinical manifestations of hyperthyroidism in adults", section on 'Metabolic/Endocrine'</a>.)</p><p class="headingAnchor" id="H28520793"><span class="h3">Hereditary hemochromatosis</span><span class="headingEndMark"> — </span>Hereditary hemochromatosis is an autosomal recessive disorder in which mutations in the <em>HFE</em> gene cause increased intestinal iron absorption and abnormal accumulation of iron in the liver, pancreas, and other organs [<a href="#rid176">176-178</a>]. Clinical manifestations include liver disease, skin pigmentation, diabetes mellitus, arthropathy, and cardiac enlargement. (See  <a class="medical medical_review" href="/z/d/html/7167.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemochromatosis"</a>.)</p><p>A generalized darkening of the skin is seen in approximately 70 percent of patients. The hyperpigmentation is due to a combination of hemosiderin deposition, which causes a diffuse, slate-gray discoloration of the skin and increased melanin production. </p><p>In patients with suspected hemochromatosis, screening tests include the measurement of serum transferrin saturation and ferritin. Genetic testing for <em>HFE</em> mutations (C282Y, H63D) should be performed in patients with elevated transferrin saturation and/or elevated ferritin to confirm the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/7157.html" rel="external">"Approach to the patient with suspected iron overload"</a>.)</p><p class="headingAnchor" id="H2097204365"><span class="h2">Primary cutaneous amyloidosis</span><span class="headingEndMark"> — </span>Primary cutaneous amyloidosis is a form of localized, organ-specific amyloidosis in which the amyloid deposition is limited to the skin. (See  <a class="medical medical_review" href="/z/d/html/13759.html" rel="external">"Cutaneous manifestations of amyloidosis"</a>.)</p><p>The pathogenesis of primary cutaneous amyloidosis is not fully understood. Prolonged friction from clothing, genetic predisposition, chronic itch-scratching cycle, and sun exposure have been proposed as possible etiologic factors, but their role remains inconclusive [<a href="#rid179">179,180</a>]. The origin of the precursor protein in primary cutaneous amyloidosis is also unclear. One hypothesis is that the fibrillar amyloid deposits are derived from keratin intermediate filament proteins [<a href="#rid181">181</a>]. </p><p>The most common types of primary cutaneous amyloidosis are macular amyloidosis, lichen amyloidosis, and biphasic amyloidosis [<a href="#rid182">182</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Macular amyloidosis</strong> – Macular amyloidosis presents with hyperpigmented, pruritic patches, exhibiting either a confluent configuration or a characteristic ripple pattern with parallel bands or ridges of hyperpigmentation  (<a class="graphic graphic_picture graphicRef94944 graphicRef94945" href="/z/d/graphic/94944.html" rel="external">picture 34A-B</a>). The rippled pattern can be best appreciated by stretching the skin. The most common site of involvement is the upper back, especially over the scapular area, followed by the extensor surfaces of the extremities. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lichen amyloidosis</strong> – Lichen amyloidosis usually presents with persistent, pruritic papules and plaques on the shins or other extensor surfaces of the extremities  (<a class="graphic graphic_picture graphicRef94969 graphicRef94971 graphicRef78571 graphicRef56616" href="/z/d/graphic/94969.html" rel="external">picture 35A-D</a>). The initial lesions are discrete, firm, scaly, skin-colored, or hyperpigmented papules, which later coalesce into plaques, often with a rippled pattern. Lesions are usually unilateral at onset but can develop into a bilateral, symmetrical distribution. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biphasic amyloidosis</strong> – In some patients, both macular and lichen amyloidosis can be present, suggesting that the two forms may represent ends of a clinical spectrum.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Amyloidosis cutis dyschromica</strong> – Amyloidosis cutis dyschromica is an exceedingly rare type of primary cutaneous amyloidosis [<a href="#rid183">183</a>]. It is characterized by reticular hyperpigmentation with hypopigmented macules distributed over nearly all of the body  (<a class="graphic graphic_picture graphicRef94996" href="/z/d/graphic/94996.html" rel="external">picture 36</a>).</p><p></p><p>The diagnosis of cutaneous amyloidosis is based upon the clinical presentation and histopathologic examination of a skin biopsy. Histology shows hyperkeratosis, necrotic keratinocytes in the basal layer, and melanophages as well as amorphous eosinophilic material (amyloid) deposits in the upper dermis. </p><p>There is no effective treatment for cutaneous amyloidosis. Several topical and systemic therapies have been tried with inconsistent results, including topical and intralesional corticosteroids, topical calcineurin inhibitors [<a href="#rid184">184</a>], systemic retinoids [<a href="#rid185">185</a>], <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> [<a href="#rid186">186</a>], <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> [<a href="#rid187">187</a>], low-dose <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and narrowband ultraviolet B (UVB) or psoralen plus ultraviolet A (PUVA) phototherapy [<a href="#rid188">188</a>]. Combination treatment (eg, ultraviolet A1 [UVA1] phototherapy and high-potency topical corticosteroids) may provide optimum results [<a href="#rid189">189</a>].</p><p class="headingAnchor" id="H1848138239"><span class="h2">Post-chikungunya fever pigmentation</span><span class="headingEndMark"> — </span>Chikungunya fever is a mosquito-borne viral illness endemic to West Africa, Southeast Asia, and the Indian subcontinent that causes acute febrile polyarthralgia and arthritis [<a href="#rid34">34,190</a>]. Other mucocutaneous manifestations are common, including a patchy or diffuse maculopapular rash that may involve the face, intertrigo-like lesions, vesicobullous lesions, and aphthous ulcerations and gingivitis [<a href="#rid191">191,192</a>]. (See  <a class="medical medical_review" href="/z/d/html/3024.html" rel="external">"Chikungunya fever: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p>Histologic examination of hyperpigmented lesions shows increased basal pigmentation, pigmentary incontinence, and melanophages  (<a class="graphic graphic_picture graphicRef93829" href="/z/d/graphic/93829.html" rel="external">picture 37</a>) [<a href="#rid34">34,190,192</a>]. These findings support the hypothesis that the hypermelanosis associated with chikungunya fever is a form of postinflammatory hyperpigmentation. </p><p>Post-chikungunya fever facial pigmentation occurs in all age groups and presents as asymptomatic, brownish-black, freckle-like macules involving the centrofacial area or diffuse pigmentation of the face  (<a class="graphic graphic_picture graphicRef93826 graphicRef93828" href="/z/d/graphic/93826.html" rel="external">picture 38A-B</a>) [<a href="#rid193">193</a>]. Other patterns of pigmentation include a melasma-like pigmentation of the face, exacerbation of a pre-existent melasma, periorbital melanosis, a flagellate pattern on the trunk and extremities, and generalized hyperpigmentation [<a href="#rid194">194</a>]. </p><p>Lesions may persist for three to six months after the infection [<a href="#rid190">190</a>]. Treatment involves sun avoidance and the use of topical corticosteroids [<a href="#rid190">190</a>].</p><p class="headingAnchor" id="H143096149"><span class="h2">Diffuse melanosis cutis</span><span class="headingEndMark"> — </span>Diffuse melanosis cutis is a rare presentation of metastatic melanoma characterized by a diffuse, blue-gray discoloration of the skin and mucosae  (<a class="graphic graphic_picture graphicRef120882" href="/z/d/graphic/120882.html" rel="external">picture 39</a>) [<a href="#rid195">195,196</a>]. Darkening of the urine (melanuria) is often associated with diffuse melanosis cutis. </p><p>Histologic examination reveals intracellular and extracellular melanin deposition in the dermis, with a pronounced perivascular distribution. It is thought that melanin and melanosome released in the circulation by cytolysis of metastatic melanoma cells are phagocytosed by dermal histiocytes, resulting in skin and mucosal discoloration.</p><p>Diffuse melanosis cutis and melanuria portend a very poor prognosis. They have also been reported in patients with advanced metastatic melanoma treated with molecularly targeted therapies and checkpoint inhibitor immunotherapy [<a href="#rid196">196,197</a>].</p><p class="headingAnchor" id="H664788"><span class="h1">GENERAL PRINCIPLES OF TREATMENT</span><span class="headingEndMark"> — </span>Treatment of cutaneous hyperpigmentation is challenging because of its chronic, persistent, and relapsing nature. The approach to treatment involves the removal of provoking factors, photoprotection, cosmetic camouflage, and a variety of pigment-reduction modalities, including topical skin-lightening agents and laser therapy [<a href="#rid198">198</a>]. However, the various treatment modalities for hyperpigmentation disorders have not been evaluated in high-quality studies. In most cases, evidence for efficacy of topical or physical therapies is based upon small series of patients or single-case reports and clinical experience.</p><p>Disorders associated with deposition of melanin in the epidermis (eg, melasma, postinflammatory hyperpigmentation) usually respond to topical skin-lightening agents. In contrast, disorders associated with deposition of melanin in the dermis do not respond to topical therapies and may be successfully treated with lasers. (See <a class="local">'Topical therapies'</a> below and  <a class="medical medical_review" href="/z/d/html/13637.html" rel="external">"Laser and light therapy for cutaneous hyperpigmentation"</a>.)</p><p>Because sunlight is a major trigger of melanin synthesis, patients with hyperpigmentation should adopt strict photoprotection measures. Cosmetic camouflage may be an option for the management of facial hyperpigmentation. (See <a class="local">'Ultraviolet and visible light protection'</a> below and <a class="local">'Cosmetic camouflage'</a> below.)</p><p class="headingAnchor" id="H664921"><span class="h2">Ultraviolet and visible light protection</span><span class="headingEndMark"> — </span>All patients with hyperpigmentation disorders associated with increased melanin production and deposition will benefit from sun avoidance and photoprotection, which involves avoiding the peak hours of sunlight (between 11:00 AM and 4:00 PM), seeking shade, wearing protective clothing (eg, broad-brimmed hats and long-sleeved shirts), and using a broad-spectrum sunscreen with sun protection factor (SPF) of at least 30. The use of tinted sunscreens that provide photoprotection against visible light, which has cutaneous biologic effects (eg, pigment darkening and erythema), is increasingly recommended for hyperpigmentation disorders [<a href="#rid199">199</a>]. (See  <a class="medical medical_review" href="/z/d/html/13751.html" rel="external">"Selection of sunscreen and sun-protective measures"</a>.)</p><p class="headingAnchor" id="H665055"><span class="h2">Cosmetic camouflage</span><span class="headingEndMark"> — </span>Physical-blocking opaque sunscreens and cosmetic coverups (in particular those containing iron oxide) have the dual benefit of camouflaging hyperpigmentation and preventing photo-induced darkening. Many of these physical blockers now come in tinted blends to assist with camouflaging. In addition, many find that the use of make-up helps to even out skin tone. (See  <a class="medical medical_review" href="/z/d/html/6621.html" rel="external">"Melasma: Management", section on 'Cosmetic camouflage'</a>.)</p><p class="headingAnchor" id="H664993"><span class="h2">Topical therapies</span><span class="headingEndMark"> — </span>Disorders associated with deposition of melanin in the epidermis (eg, melasma, postinflammatory hyperpigmentation) can be often successfully treated with topical skin-lightening agents. These include <a class="drug drug_general" data-topicid="8539" href="/z/d/drug information/8539.html" rel="external">hydroquinone</a>, <a class="drug drug_general" data-topicid="9038" href="/z/d/drug information/9038.html" rel="external">azelaic acid</a>, mequinol, kojic acid, tretinoin, <a class="drug drug_general" data-topicid="9313" href="/z/d/drug information/9313.html" rel="external">cysteamine</a>, and several combinations of topical agents. Topical skin-lightening agents are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6621.html" rel="external">"Melasma: Management", section on 'Topical skin-lightening agents'</a>.)</p><p class="headingAnchor" id="H2800404037"><span class="h2">Chemical peels</span><span class="headingEndMark"> — </span>Chemical peels are an increasingly popular method for removal of hyperpigmentation. Common peeling agents include alpha-hydroxy acids (eg, glycolic acid), beta-hydroxy acids (eg, salicylic acid), <a class="drug drug_general" data-topicid="10296" href="/z/d/drug information/10296.html" rel="external">trichloroacetic acid</a>, Jessner's solution, and retinoids. In skin of color, superficial to medium-depth peels are most typically used to reduce the risk of scarring and dyspigmentation. (See  <a class="medical medical_review" href="/z/d/html/121148.html" rel="external">"Chemical peels: Principles, peeling agents, and pretreatment assessment"</a> and  <a class="medical medical_review" href="/z/d/html/13632.html" rel="external">"Chemical peels: Procedures and complications"</a>.)</p><p class="headingAnchor" id="H665122"><span class="h2">Laser therapy</span><span class="headingEndMark"> — </span>Hyperpigmentation disorders associated with melanin deposition in the dermis (eg, nevus of Ota, nevus of Hori) do not respond to topical therapies but can be often successfully treated with laser therapy [<a href="#rid26">26</a>]. In particular, quality-switched (Q-switched) lasers (eg, 1064 nm Q-switched neodymium-doped yttrium aluminum garnet [Nd:YAG]) and picosecond lasers are widely used for patients with darkly pigmented skin because of longer wavelengths and short pulse durations, which allow for safe treatment.</p><p>The use of lasers for the treatment of specific hyperpigmentation disorders is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/13637.html" rel="external">"Laser and light therapy for cutaneous hyperpigmentation"</a>.)</p><p class="headingAnchor" id="H3334481475"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/129725.html" rel="external">"Society guideline links: Melasma and hyperpigmentation disorders"</a>.)</p><p class="headingAnchor" id="H1566687"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology </strong>– In most cases, skin hyperpigmentation is caused by increased biosynthesis and deposition of melanin (hypermelanosis) in the epidermis and/or dermis. Epidermal hypermelanosis results from an excess of melanin in the basal and suprabasal layers of the skin due to increased melanin production. These abnormalities may be due to both acquired and genetic factors. (See <a class="local">'Pathophysiology of hyperpigmentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient evaluation and diagnosis</strong> – The diagnosis of most hyperpigmentation disorders is made on clinical grounds. The initial patient evaluation involves a detailed medical history and a complete skin examination. Investigation of family history may be helpful to determine whether the disorder is acquired or inherited. Skin examination should be performed under visible light and Wood's light. Important clinical parameters include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Extent of the pigmentary abnormality</p><p class="bulletIndent2"><span class="glyph">•</span>Color hue</p><p class="bulletIndent2"><span class="glyph">•</span>Morphology of individual lesions </p><p class="bulletIndent2"><span class="glyph">•</span>Distribution (circumscribed or diffuse)</p><p class="bulletIndent2"><span class="glyph">•</span>Pattern (linear, reticulate, nonpatterned)</p><p class="bulletIndent2"><span class="glyph">•</span>Stable or progressing </p><p class="bulletIndent2"><span class="glyph">•</span>Association with inflammation/cutaneous injury</p><p></p><p class="bulletIndent1">An algorithmic approach to the diagnosis, based upon history and clinical parameters, is shown in the figure  (<a class="graphic graphic_algorithm graphicRef93949" href="/z/d/graphic/93949.html" rel="external">algorithm 1</a>). (See <a class="local">'Patient evaluation and diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specific disorders</strong> – Characteristics of specific disorders and their evaluation are described above. (See <a class="local">'Circumscribed hyperpigmentation'</a> above and <a class="local">'Onset in childhood/adolescence'</a> above and <a class="local">'Onset in adulthood'</a> above and <a class="local">'Patterned hyperpigmentation'</a> above and <a class="local">'Diffuse nonpatterned hyperpigmentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Treatment of cutaneous hyperpigmentation is challenging because of its chronic, persistent, and relapsing nature. The approach to management involves the removal of provoking factors, photoprotection from both ultraviolet and visible light, cosmetic camouflage, and a variety of pigment-reduction modalities, including topical skin-lightening agents and laser therapy. (See <a class="local">'General principles of treatment'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Alexis AF, Sergay AB, Taylor SC. Common dermatologic disorders in skin of color: a comparative practice survey. Cutis 2007; 80:387.</a></li><li><a class="nounderline abstract_t">Nordlund JJ, Cestari TF, Chan H, Westerhof W. Confusions about colour: a classification of discolorations of the skin. Br J Dermatol 2006; 156 Suppl 1:3.</a></li><li class="breakAll">Lapeere H, Boone B, De Schepper S, et al. Hypomelanoses and hypermelanoses. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith LA, Katz SI, Gilchrest BA, et al (Eds), McGraw-Hill, 2012. Vol 1, p.804.</li><li><a class="nounderline abstract_t">Kang SJ, Davis SA, Feldman SR, McMichael AJ. Dyschromia in skin of color. J Drugs Dermatol 2014; 13:401.</a></li><li><a class="nounderline abstract_t">Davis SA, Narahari S, Feldman SR, et al. Top dermatologic conditions in patients of color: an analysis of nationally representative data. J Drugs Dermatol 2012; 11:466.</a></li><li><a class="nounderline abstract_t">Maymone MBC, Neamah HH, Wirya SA, et al. The impact of skin hyperpigmentation and hyperchromia on quality of life: A cross-sectional study. J Am Acad Dermatol 2017; 77:775.</a></li><li class="breakAll">Ito S, Wakamatsu K. Chemistry of melanins. In: The Pigmentary System: Physiology and Pathophysiology, 2nd ed, Nordlund JJ, Boissy RE, Hearing VJ, et al (Eds), Blackwell Publishing Ltd, 2006. p.282.</li><li><a class="nounderline abstract_t">Speeckaert R, Van Gele M, Speeckaert MM, et al. The biology of hyperpigmentation syndromes. Pigment Cell Melanoma Res 2014; 27:512.</a></li><li><a class="nounderline abstract_t">Taylor SC. Skin of color: biology, structure, function, and implications for dermatologic disease. J Am Acad Dermatol 2002; 46:S41.</a></li><li><a class="nounderline abstract_t">Szabó G, Gerald AB, Pathak MA, Fitzpatrick TB. Racial differences in the fate of melanosomes in human epidermis. Nature 1969; 222:1081.</a></li><li><a class="nounderline abstract_t">Ranu H, Thng S, Goh BK, et al. Periorbital hyperpigmentation in Asians: an epidemiologic study and a proposed classification. Dermatol Surg 2011; 37:1297.</a></li><li><a class="nounderline abstract_t">Lambert MW, Maddukuri S, Karanfilian KM, et al. The physiology of melanin deposition in health and disease. Clin Dermatol 2019; 37:402.</a></li><li><a class="nounderline abstract_t">Wang RF, Ko D, Friedman BJ, et al. Disorders of hyperpigmentation. Part I. Pathogenesis and clinical features of common pigmentary disorders. J Am Acad Dermatol 2023; 88:271.</a></li><li><a class="nounderline abstract_t">Chuh AA, Wong WC, Wong SY, Lee A. Procedures in primary care dermatology. Aust Fam Physician 2005; 34:347.</a></li><li><a class="nounderline abstract_t">Grimes PE, Yamada N, Bhawan J. Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma. Am J Dermatopathol 2005; 27:96.</a></li><li><a class="nounderline abstract_t">Gilchrest BA, Fitzpatrick TB, Anderson RR, Parrish JA. Localization of malanin pigmentation in the skin with Wood's lamp. Br J Dermatol 1977; 96:245.</a></li><li><a class="nounderline abstract_t">Krueger L, Saizan A, Stein JA, Elbuluk N. Dermoscopy of acquired pigmentary disorders: a comprehensive review. Int J Dermatol 2022; 61:7.</a></li><li><a class="nounderline abstract_t">Kang HY, Bahadoran P, Suzuki I, et al. In vivo reflectance confocal microscopy detects pigmentary changes in melasma at a cellular level resolution. Exp Dermatol 2010; 19:e228.</a></li><li><a class="nounderline abstract_t">Calzavara-Pinton P, Longo C, Venturini M, et al. Reflectance confocal microscopy for in vivo skin imaging. Photochem Photobiol 2008; 84:1421.</a></li><li><a class="nounderline abstract_t">Hofmann-Wellenhof R, Wurm EM, Ahlgrimm-Siess V, et al. Reflectance confocal microscopy--state-of-art and research overview. Semin Cutan Med Surg 2009; 28:172.</a></li><li><a class="nounderline abstract_t">Kang HY, Bahadoran P, Ortonne JP. Reflectance confocal microscopy for pigmentary disorders. Exp Dermatol 2010; 19:233.</a></li><li><a class="nounderline abstract_t">Ardigo M, Cameli N, Berardesca E, Gonzalez S. Characterization and evaluation of pigment distribution and response to therapy in melasma using in vivo reflectance confocal microscopy: a preliminary study. J Eur Acad Dermatol Venereol 2010; 24:1296.</a></li><li><a class="nounderline abstract_t">Yamaguchi K, Watanabe C, Kawaguchi A, et al. Association of melanocortin 1 receptor gene (MC1R) polymorphisms with skin reflectance and freckles in Japanese. J Hum Genet 2012; 57:700.</a></li><li><a class="nounderline abstract_t">Bastiaens M, ter Huurne J, Gruis N, et al. The melanocortin-1-receptor gene is the major freckle gene. Hum Mol Genet 2001; 10:1701.</a></li><li><a class="nounderline abstract_t">Bliss JM, Ford D, Swerdlow AJ, et al. Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE). Int J Cancer 1995; 62:367.</a></li><li><a class="nounderline abstract_t">Polder KD, Landau JM, Vergilis-Kalner IJ, et al. Laser eradication of pigmented lesions: a review. Dermatol Surg 2011; 37:572.</a></li><li><a class="nounderline abstract_t">Yaşar Ş, Ersanli A, Göktay F, et al. Partial unilateral lentiginosis is mosaic neurofibromatosis type 1 or not? J Dermatol 2017; 44:29.</a></li><li><a class="nounderline abstract_t">Kim HT, Choi ME, Na H, et al. Partial unilateral lentiginosis: a clinicopathological analysis of 32 cases on the head and neck area in Korea. Int J Dermatol 2021; 60:1376.</a></li><li><a class="nounderline abstract_t">González-Sixto B, De la Torre C, Posada C, Sevillano C. Partial unilateral lentiginosis associated with nevus of Ota. J Am Acad Dermatol 2010; 63:353.</a></li><li><a class="nounderline abstract_t">Chen W, Fan PC, Happle R. Partial unilateral lentiginosis with ipsilateral Lisch nodules and axillary freckling. Dermatology 2004; 209:321.</a></li><li><a class="nounderline abstract_t">Lee Y, Choi EH, Lee SW. Low-fluence Q-switched 1,064-nm neodymium-doped yttrium aluminum garnet laser for the treatment of facial partial unilateral lentiginosis in Koreans. Dermatol Surg 2012; 38:31.</a></li><li><a class="nounderline abstract_t">Pretel M, Irarrazaval I, Aguado L, et al. Partial unilateral lentiginosis treated with alexandrite Q-switched laser: case report and review of the literature. J Cosmet Laser Ther 2013; 15:207.</a></li><li><a class="nounderline abstract_t">Sardana K, Relhan V, Garg V, Khurana N. An observational analysis of erythromelanosis follicularis faciei et colli. Clin Exp Dermatol 2008; 33:333.</a></li><li><a class="nounderline abstract_t">Khanna N, Rasool S. Facial melanoses: Indian perspective. Indian J Dermatol Venereol Leprol 2011; 77:552.</a></li><li><a class="nounderline abstract_t">Kim WJ, Song M, Ko HC, et al. Topical tacalcitol ointment can be a good therapeutic choice in erythromelanosis follicularis faciei et colli. J Am Acad Dermatol 2012; 67:320.</a></li><li><a class="nounderline abstract_t">Li YH, Zhu X, Chen JZ, et al. Treatment of erythromelanosis follicularis faciei et colli using a dual-wavelength laser system: a split-face treatment. Dermatol Surg 2010; 36:1344.</a></li><li><a class="nounderline abstract_t">Dedhia A, Someshwar S, Jerajani HR. Idiopathic eruptive macular pigmentation: What is it actually? Int J Dermatol 2015; 54:1462.</a></li><li><a class="nounderline abstract_t">Sanz de Galdeano C, Léauté-Labrèze C, Bioulac-Sage P, et al. Idiopathic eruptive macular pigmentation: report of five patients. Pediatr Dermatol 1996; 13:274.</a></li><li><a class="nounderline abstract_t">Chandran V, Kumarasinghe SP. Macular pigmentation of uncertain aetiology revisited: two case reports and a proposed algorithm for clinical classification. Australas J Dermatol 2017; 58:45.</a></li><li><a class="nounderline abstract_t">Verma S, Thakur BK. Idiopathic eruptive macular pigmentation with papillomatosis. Indian Dermatol Online J 2011; 2:101.</a></li><li><a class="nounderline abstract_t">Berk DR. Terra firma-forme dermatosis: a retrospective review of 31 patients. Pediatr Dermatol 2012; 29:297.</a></li><li><a class="nounderline abstract_t">Greywal T, Cohen PR. Terra firma-forme dermatosis: A report of ten individuals with Duncan's dirty dermatosis and literature review. Dermatol Pract Concept 2015; 5:29.</a></li><li><a class="nounderline abstract_t">Kim GH, Mikkilineni R. Lichen planus actinicus. Dermatol Online J 2007; 13:13.</a></li><li><a class="nounderline abstract_t">Dammak A, Masmoudi A, Boudaya S, et al. [Childhood actinic lichen planus (6 cases)]. Arch Pediatr 2008; 15:111.</a></li><li><a class="nounderline abstract_t">Meads SB, Kunishige J, Ramos-Caro FA, Hassanein AM. Lichen planus actinicus. Cutis 2003; 72:377.</a></li><li class="breakAll">Shiohara T, Kano Y. Lichen planus and lichenoid dermatoses. In: Dermatology, 3rd ed, Jorizzo JL, Bolognia JL, Schaffer JV (Eds), Elsevier Saunders, 2012. Vol 1, p.183.</li><li><a class="nounderline abstract_t">Ramírez P, Feito M, Sendagorta E, et al. Childhood actinic lichen planus: successful treatment with antimalarials. Australas J Dermatol 2012; 53:e10.</a></li><li><a class="nounderline abstract_t">Jansen T, Gambichler T, von Kobyletzki L, Altmeyer P. Lichen planus actinicus treated with acitretin and topical corticosteroids. J Eur Acad Dermatol Venereol 2002; 16:174.</a></li><li><a class="nounderline abstract_t">Gallo L, Ayala F, Ayala F. Relapsing lichen actinicus successfully treated with cyclosporin. J Eur Acad Dermatol Venereol 2008; 22:370.</a></li><li><a class="nounderline abstract_t">Ortonne JP, Pandya AG, Lui H, Hexsel D. Treatment of solar lentigines. J Am Acad Dermatol 2006; 54:S262.</a></li><li><a class="nounderline abstract_t">Rhodes AR, Harrist TJ, Momtaz-T K. The PUVA-induced pigmented macule: a lentiginous proliferation of large, sometimes cytologically atypical, melanocytes. J Am Acad Dermatol 1983; 9:47.</a></li><li><a class="nounderline abstract_t">Friedland R, David M, Feinmesser M, et al. NB-UVB (311-312 nm)-induced lentigines in patients with mycosis fungoides: a new adverse effect of phototherapy. J Eur Acad Dermatol Venereol 2012; 26:1158.</a></li><li><a class="nounderline abstract_t">Shah KR, Boland CR, Patel M, et al. Cutaneous manifestations of gastrointestinal disease: part I. J Am Acad Dermatol 2013; 68:189.e1.</a></li><li><a class="nounderline abstract_t">Devulder F, Bouché O, Diebold MD, et al. [Cronkhite-Canada syndrome: a new French case]. Gastroenterol Clin Biol 1999; 23:407.</a></li><li><a class="nounderline abstract_t">Watanabe C, Komoto S, Tomita K, et al. Endoscopic and clinical evaluation of treatment and prognosis of Cronkhite-Canada syndrome: a Japanese nationwide survey. J Gastroenterol 2016; 51:327.</a></li><li><a class="nounderline abstract_t">Veraitch O, Rickaby W, Robson A, et al. Early-onset dermatosis papulosa nigra. Br J Dermatol 2016; 174:1148.</a></li><li><a class="nounderline abstract_t">Babapour R, Leach J, Levy H. Dermatosis papulosa nigra in a young child. Pediatr Dermatol 1993; 10:356.</a></li><li><a class="nounderline abstract_t">Hafner C, Landthaler M, Mentzel T, Vogt T. FGFR3 and PIK3CA mutations in stucco keratosis and dermatosis papulosa nigra. Br J Dermatol 2010; 162:508.</a></li><li><a class="nounderline abstract_t">Maghfour J, Ogunleye T. A Systematic Review on the Treatment of Dermatosis Papulosa Nigra. J Drugs Dermatol 2021; 20:467.</a></li><li><a class="nounderline abstract_t">Tran M, Richer V. Elective Treatment of Dermatosis Papulosa Nigra: A Review of Treatment Modalities. Skin Therapy Lett 2020; 25:1.</a></li><li><a class="nounderline abstract_t">Lupo MP. Dermatosis papulosis nigra: treatment options. J Drugs Dermatol 2007; 6:29.</a></li><li><a class="nounderline abstract_t">Garcia MS, Azari R, Eisen DB. Treatment of dermatosis papulosa nigra in 10 patients: a comparison trial of electrodesiccation, pulsed dye laser, and curettage. Dermatol Surg 2010; 36:1968.</a></li><li><a class="nounderline abstract_t">Kundu RV, Joshi SS, Suh KY, et al. Comparison of electrodesiccation and potassium-titanyl-phosphate laser for treatment of dermatosis papulosa nigra. Dermatol Surg 2009; 35:1079.</a></li><li><a class="nounderline abstract_t">Ali FR, Bakkour W, Ferguson JE, Madan V. Carbon dioxide laser ablation of dermatosis papulosa nigra: high satisfaction and few complications in patients with pigmented skin. Lasers Med Sci 2016; 31:593.</a></li><li><a class="nounderline abstract_t">Bruscino N, Conti R, Campolmi P, et al. Dermatosis Papulosa Nigra and 10,600-nm CO2 laser, a good choice. J Cosmet Laser Ther 2014; 16:114.</a></li><li><a class="nounderline abstract_t">Katz TM, Goldberg LH, Friedman PM. Dermatosis papulosa nigra treatment with fractional photothermolysis. Dermatol Surg 2009; 35:1840.</a></li><li><a class="nounderline abstract_t">Baumann LS, Blauvelt A, Draelos ZD, et al. Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: Results from 2 identical, randomized, double-blind, placebo-controlled, phase 3 studies (A-101-SEBK-301/302). J Am Acad Dermatol 2018; 79:869.</a></li><li class="breakAll">Alexander AM. Maturational hyperpigmentation. In: Dermatology for Skin of Color, Kelly AP, Taylor SC (Eds), McGraw-Hill, 2009.</li><li><a class="nounderline abstract_t">Roh MR, Chung KY. Infraorbital dark circles: definition, causes, and treatment options. Dermatol Surg 2009; 35:1163.</a></li><li><a class="nounderline abstract_t">Sarkar R. Idiopathic cutaneous hyperchromia at the orbital region or periorbital hyperpigmentation. J Cutan Aesthet Surg 2012; 5:183.</a></li><li><a class="nounderline abstract_t">Goodman RM, Belcher RW. Periorbital hyperpigmentation. An overlooked genetic disorder of pigmentation. Arch Dermatol 1969; 100:169.</a></li><li><a class="nounderline abstract_t">Malakar S, Lahiri K, Banerjee U, et al. Periorbital melanosis is an extension of pigmentary demarcation line-F on face. Indian J Dermatol Venereol Leprol 2007; 73:323.</a></li><li><a class="nounderline abstract_t">Watanabe S, Nakai K, Ohnishi T. Condition known as "dark rings under the eyes" in the Japanese population is a kind of dermal melanocytosis which can be successfully treated by Q-switched ruby laser. Dermatol Surg 2006; 32:785.</a></li><li><a class="nounderline abstract_t">Graziosi AC, Quaresma MR, Michalany NS, Ferreira LM. Cutaneous idiopathic hyperchromia of the orbital region (CIHOR): a histopathological study. Aesthetic Plast Surg 2013; 37:434.</a></li><li><a class="nounderline abstract_t">Vavouli C, Katsambas A, Gregoriou S, et al. Chemical peeling with trichloroacetic acid and lactic acid for infraorbital dark circles. J Cosmet Dermatol 2013; 12:204.</a></li><li><a class="nounderline abstract_t">Ma G, Lin XX, Hu XJ, et al. Treatment of venous infraorbital dark circles using a long-pulsed 1,064-nm neodymium-doped yttrium aluminum garnet laser. Dermatol Surg 2012; 38:1277.</a></li><li><a class="nounderline abstract_t">Xu TH, Yang ZH, Li YH, et al. Treatment of infraorbital dark circles using a low-fluence Q-switched 1,064-nm laser. Dermatol Surg 2011; 37:797.</a></li><li><a class="nounderline abstract_t">Momosawa A, Kurita M, Ozaki M, et al. Combined therapy using Q-switched ruby laser and bleaching treatment with tretinoin and hydroquinone for periorbital skin hyperpigmentation in Asians. Plast Reconstr Surg 2008; 121:282.</a></li><li><a class="nounderline abstract_t">Youn S, Shin JI, Kim JD, et al. Correction of infraorbital dark circles using collagenase-digested fat cell grafts. Dermatol Surg 2013; 39:766.</a></li><li><a class="nounderline abstract_t">Sharad J. Dermal Fillers for the Treatment of Tear Trough Deformity: A Review of Anatomy, Treatment Techniques, and their Outcomes. J Cutan Aesthet Surg 2012; 5:229.</a></li><li><a class="nounderline abstract_t">Bernardini FP, Cetinkaya A, Devoto MH, Zambelli A. Calcium hydroxyl-apatite (Radiesse) for the correction of periorbital hollows, dark circles, and lower eyelid bags. Ophthal Plast Reconstr Surg 2014; 30:34.</a></li><li><a class="nounderline abstract_t">Sheth VM, Pandya AG. Melasma: a comprehensive update: part I. J Am Acad Dermatol 2011; 65:689.</a></li><li><a class="nounderline abstract_t">Cestari TF, Dantas LP, Boza JC. Acquired hyperpigmentations. An Bras Dermatol 2014; 89:11.</a></li><li><a class="nounderline abstract_t">Katoulis AC, Stavrianeas NG, Panayiotides JG, et al. Poikiloderma of Civatte: a histopathological and ultrastructural study. Dermatology 2007; 214:177.</a></li><li><a class="nounderline abstract_t">Scattone L, de Avelar Alchorne MM, Michalany N, et al. Histopathologic changes induced by intense pulsed light in the treatment of poikiloderma of Civatte. Dermatol Surg 2012; 38:1010.</a></li><li><a class="nounderline abstract_t">Rusciani A, Motta A, Fino P, Menichini G. Treatment of poikiloderma of Civatte using intense pulsed light source: 7 years of experience. Dermatol Surg 2008; 34:314.</a></li><li><a class="nounderline abstract_t">Goldman MP, Weiss RA. Treatment of poikiloderma of Civatte on the neck with an intense pulsed light source. Plast Reconstr Surg 2001; 107:1376.</a></li><li><a class="nounderline abstract_t">Weiss RA, Goldman MP, Weiss MA. Treatment of poikiloderma of Civatte with an intense pulsed light source. Dermatol Surg 2000; 26:823.</a></li><li><a class="nounderline abstract_t">Kumarasinghe SPW, Pandya A, Chandran V, et al. A global consensus statement on ashy dermatosis, erythema dyschromicum perstans, lichen planus pigmentosus, idiopathic eruptive macular pigmentation, and Riehl's melanosis. Int J Dermatol 2019; 58:263.</a></li><li><a class="nounderline abstract_t">Schwartz RA. Erythema dyschromicum perstans: the continuing enigma of Cinderella or ashy dermatosis. Int J Dermatol 2004; 43:230.</a></li><li><a class="nounderline abstract_t">Torrelo A, Zaballos P, Colmenero I, et al. Erythema dyschromicum perstans in children: a report of 14 cases. J Eur Acad Dermatol Venereol 2005; 19:422.</a></li><li class="breakAll">Chang MW. Disorders of hyperpigmentation. In: Dermatology, 3rd ed, Jorizzo JL, Bolognia JL, Schaffer JV (Eds), Elsevier Saunders, 2012. Vol 1, p.1049.</li><li><a class="nounderline abstract_t">Nelson MR, Lawrence AG, Staughton RC, Gazzard BG. Erythema dyschromicum perstans in an HIV antibody-positive man. Br J Dermatol 1992; 127:658.</a></li><li><a class="nounderline abstract_t">Lambert WC, Schwartz RA, Hamilton GB. Erythema dyschromicum perstans. Cutis 1986; 37:42.</a></li><li><a class="nounderline abstract_t">Correa MC, Memije EV, Vargas-Alarcón G, et al. HLA-DR association with the genetic susceptibility to develop ashy dermatosis in Mexican Mestizo patients. J Am Acad Dermatol 2007; 56:617.</a></li><li class="breakAll">Mobini N, Toussaint S, Kamino H. Noninfectious erythematous, papular, and squamous diseases. In: Lever's Histopathology of the Skin, Elder DE, Elenitsas R, Johnson BL, et al (Eds), Lippincott Williams &amp; Wilkins, 2009. p.172.</li><li><a class="nounderline abstract_t">Mahajan VK, Chauhan PS, Mehta KS, Sharma AL. Erythema Dyschromicum Perstans: Response to Topical Tacrolimus. Indian J Dermatol 2015; 60:525.</a></li><li><a class="nounderline abstract_t">Bahadir S, Cobanoglu U, Cimsit G, et al. Erythema dyschromicum perstans: response to dapsone therapy. Int J Dermatol 2004; 43:220.</a></li><li><a class="nounderline abstract_t">Baranda L, Torres-Alvarez B, Cortes-Franco R, et al. Involvement of cell adhesion and activation molecules in the pathogenesis of erythema dyschromicum perstans (ashy dermatitis). The effect of clofazimine therapy. Arch Dermatol 1997; 133:325.</a></li><li><a class="nounderline abstract_t">Piquero-Martín J, Pérez-Alfonzo R, Abrusci V, et al. Clinical trial with clofazimine for treating erythema dyschromicum perstans. Evaluation of cell-mediated immunity. Int J Dermatol 1989; 28:198.</a></li><li><a class="nounderline abstract_t">Wang F, Zhao YK, Wang Z, et al. Erythema Dyschromicum Perstans Response to Isotretinoin. JAMA Dermatol 2016; 152:841.</a></li><li><a class="nounderline abstract_t">Leung N, Oliveira M, Selim MA, et al. Erythema dyschromicum perstans: A case report and systematic review of histologic presentation and treatment. Int J Womens Dermatol 2018; 4:216.</a></li><li><a class="nounderline abstract_t">Silverberg NB, Herz J, Wagner A, Paller AS. Erythema dyschromicum perstans in prepubertal children. Pediatr Dermatol 2003; 20:398.</a></li><li><a class="nounderline abstract_t">Rieder E, Kaplan J, Kamino H, et al. Lichen planus pigmentosus. Dermatol Online J 2013; 19:20713.</a></li><li><a class="nounderline abstract_t">Kanwar AJ, Dogra S, Handa S, et al. A study of 124 Indian patients with lichen planus pigmentosus. Clin Exp Dermatol 2003; 28:481.</a></li><li><a class="nounderline abstract_t">Haber R, Dib N, Gemayel ME. Lichen Planus Pigmentosus Associated with Topical Olive Oil Application. Skinmed 2021; 19:142.</a></li><li><a class="nounderline abstract_t">Marques LC, Santos LR, da Silva NC, et al. Oral Lichen Planus Associated With Lichen Planus Pigmentosus and Lichen Sclerosus in Monozygotic Twins. Am J Dermatopathol 2021; 43:368.</a></li><li><a class="nounderline abstract_t">Dlova NC. Frontal fibrosing alopecia and lichen planus pigmentosus: is there a link? Br J Dermatol 2013; 168:439.</a></li><li><a class="nounderline abstract_t">Pirmez R, Duque-Estrada B, Donati A, et al. Clinical and dermoscopic features of lichen planus pigmentosus in 37 patients with frontal fibrosing alopecia. Br J Dermatol 2016; 175:1387.</a></li><li><a class="nounderline abstract_t">Al-Mutairi N, El-Khalawany M. Clinicopathological characteristics of lichen planus pigmentosus and its response to tacrolimus ointment: an open label, non-randomized, prospective study. J Eur Acad Dermatol Venereol 2010; 24:535.</a></li><li><a class="nounderline abstract_t">Kim JE, Won CH, Chang S, et al. Linear lichen planus pigmentosus of the forehead treated by neodymium:yttrium-aluminum-garnet laser and topical tacrolimus. J Dermatol 2012; 39:189.</a></li><li><a class="nounderline abstract_t">Han XD, Goh CL. A case of lichen planus pigmentosus that was recalcitrant to topical treatment responding to pigment laser treatment. Dermatol Ther 2014; 27:264.</a></li><li><a class="nounderline abstract_t">Wu CY, Lin FL. A successful combination therapy of tacrolimus, hydroxychloroquine and picosecond laser for lichen planus pigmentosus. Australas J Dermatol 2019; 60:e336.</a></li><li><a class="nounderline abstract_t">Shah P, Ugonabo N, Liebman TN. A case of recalcitrant lichen planus pigmentosus treated by oral isotretinoin. JAAD Case Rep 2020; 6:812.</a></li><li><a class="nounderline abstract_t">rorsman H. Riehl's melanosis. Int J Dermatol 1982; 21:75.</a></li><li class="breakAll">Bangert S, Levine N. Riehl's melanosis. In: The Pigmentary System: Physiology and Pathophysiology, 2nd ed, Nordlund JJ, Boissy RE, Hearing VJ, et al (Eds), Blackwell Publishing, 2006. p.961.</li><li><a class="nounderline abstract_t">Bovenschen HJ, Seyger MM. Erythrosis pigmentosa mediofacialis: familial occurrence. Acta Derm Venereol 2009; 89:210.</a></li><li><a class="nounderline abstract_t">Juhlin L, Alkemade H. Erythrosis pigmentosa mediofacialis (Brocq) and erythromelanosis follicularis faciei et colli in the same patient. Acta Derm Venereol 1999; 79:65.</a></li><li><a class="nounderline abstract_t">Pérez-Bernal A, Muñoz-Pérez MA, Camacho F. Management of facial hyperpigmentation. Am J Clin Dermatol 2000; 1:261.</a></li><li><a class="nounderline abstract_t">Hori Y, Kawashima M, Oohara K, Kukita A. Acquired, bilateral nevus of Ota-like macules. J Am Acad Dermatol 1984; 10:961.</a></li><li><a class="nounderline abstract_t">Park JM, Tsao H, Tsao S. Acquired bilateral nevus of Ota-like macules (Hori nevus): etiologic and therapeutic considerations. J Am Acad Dermatol 2009; 61:88.</a></li><li><a class="nounderline abstract_t">Ee HL, Wong HC, Goh CL, Ang P. Characteristics of Hori naevus: a prospective analysis. Br J Dermatol 2006; 154:50.</a></li><li><a class="nounderline abstract_t">Ee HL, Goh CL, Khoo LS, et al. Treatment of acquired bilateral nevus of ota-like macules (Hori's nevus) with a combination of the 532 nm Q-Switched Nd:YAG laser followed by the 1,064 nm Q-switched Nd:YAG is more effective: prospective study. Dermatol Surg 2006; 32:34.</a></li><li><a class="nounderline abstract_t">Cho SB, Park SJ, Kim MJ, Bu TS. Treatment of acquired bilateral nevus of Ota-like macules (Hori's nevus) using 1064-nm Q-switched Nd:YAG laser with low fluence. Int J Dermatol 2009; 48:1308.</a></li><li><a class="nounderline abstract_t">Kunachak S, Leelaudomlipi P, Sirikulchayanonta V. Q-Switched ruby laser therapy of acquired bilateral nevus of Ota-like macules. Dermatol Surg 1999; 25:938.</a></li><li><a class="nounderline abstract_t">Polnikorn N, Tanrattanakorn S, Goldberg DJ. Treatment of Hori's nevus with the Q-switched Nd:YAG laser. Dermatol Surg 2000; 26:477.</a></li><li><a class="nounderline abstract_t">Suh DH, Han KH, Chung JH. Clinical use of the Q-switched Nd:YAG laser for the treatment of acquired bilateral nevus of Ota-like macules (ABNOMs) in Koreans. J Dermatolog Treat 2001; 12:163.</a></li><li><a class="nounderline abstract_t">Rongioletti F, Rebora A. Acquired brachial cutaneous dyschromatosis: a common pigmentary disorder of the arm in middle-aged women. J Am Acad Dermatol 2000; 42:680.</a></li><li><a class="nounderline abstract_t">Hu SW, Chu J, Meehan S, et al. Acquired brachial cutaneous dyschromatosis. Dermatol Online J 2011; 17:16.</a></li><li><a class="nounderline abstract_t">Levin CY, Maibach H. Exogenous ochronosis. An update on clinical features, causative agents and treatment options. Am J Clin Dermatol 2001; 2:213.</a></li><li><a class="nounderline abstract_t">Merola JF, Meehan S, Walters RF, Brown L. Exogenous ochronosis. Dermatol Online J 2008; 14:6.</a></li><li><a class="nounderline abstract_t">Hardwick N, Van Gelder LW, Van der Merwe CA, Van der Merwe MP. Exogenous ochronosis: an epidemiological study. Br J Dermatol 1989; 120:229.</a></li><li><a class="nounderline abstract_t">Olumide YM, Akinkugbe AO, Altraide D, et al. Complications of chronic use of skin lightening cosmetics. Int J Dermatol 2008; 47:344.</a></li><li><a class="nounderline abstract_t">Charlín R, Barcaui CB, Kac BK, et al. Hydroquinone-induced exogenous ochronosis: a report of four cases and usefulness of dermoscopy. Int J Dermatol 2008; 47:19.</a></li><li><a class="nounderline abstract_t">Diven DG, Smith EB, Pupo RA, Lee M. Hydroquinone-induced localized exogenous ochronosis treated with dermabrasion and CO2 laser. J Dermatol Surg Oncol 1990; 16:1018.</a></li><li><a class="nounderline abstract_t">Kanechorn-Na-Ayuthaya P, Niumphradit N, Aunhachoke K, et al. Effect of combination of 1064 nm Q-switched Nd:YAG and fractional carbon dioxide lasers for treating exogenous ochronosis. J Cosmet Laser Ther 2013; 15:42.</a></li><li><a class="nounderline abstract_t">Simmons BJ, Griffith RD, Bray FN, et al. Exogenous ochronosis: a comprehensive review of the diagnosis, epidemiology, causes, and treatments. Am J Clin Dermatol 2015; 16:205.</a></li><li><a class="nounderline abstract_t">Chaptini C, Huilgol SC. Erbium-doped yttrium aluminium garnet ablative laser treatment for endogenous ochronosis. Australas J Dermatol 2015; 56:212.</a></li><li><a class="nounderline abstract_t">Tan SK. Exogenous ochronosis - successful outcome after treatment with Q-switched Nd:YAG laser. J Cosmet Laser Ther 2013; 15:274.</a></li><li><a class="nounderline abstract_t">Bellew SG, Alster TS. Treatment of exogenous ochronosis with a Q-switched alexandrite (755 nm) laser. Dermatol Surg 2004; 30:555.</a></li><li><a class="nounderline abstract_t">Smith MH, Bhattacharyya I, Cohen DM, et al. Melanoma of the Oral Cavity: an Analysis of 46 New Cases with Emphasis on Clinical and Histopathologic Characteristics. Head Neck Pathol 2016; 10:298.</a></li><li><a class="nounderline abstract_t">Nayak RS, Kotrashetti VS, Hosmani JV. Laugier-Hunziker syndrome. J Oral Maxillofac Pathol 2012; 16:245.</a></li><li><a class="nounderline abstract_t">Sheridan AT, Dawber RP. Laugier-Hunziker syndrome: treatment with cryosurgery. J Eur Acad Dermatol Venereol 1999; 13:146.</a></li><li><a class="nounderline abstract_t">Zuo YG, Ma DL, Jin HZ, et al. Treatment of Laugier-Hunziker syndrome with the Q-switched alexandrite laser in 22 Chinese patients. Arch Dermatol Res 2010; 302:125.</a></li><li><a class="nounderline abstract_t">Ferreira MJ, Ferreira AM, Soares AP, Rodrigues JC. Laugier-Hunziker syndrome: case report and treatment with the Q-switched Nd-Yag laser. J Eur Acad Dermatol Venereol 1999; 12:171.</a></li><li><a class="nounderline abstract_t">Axéll T, Hedin CA. Epidemiologic study of excessive oral melanin pigmentation with special reference to the influence of tobacco habits. Scand J Dent Res 1982; 90:434.</a></li><li><a class="nounderline abstract_t">Nwhator SO, Winfunke-Savage K, Ayanbadejo P, Jeboda SO. Smokers' melanosis in a Nigerian population: a preliminary study. J Contemp Dent Pract 2007; 8:68.</a></li><li><a class="nounderline abstract_t">Taybos G. Oral changes associated with tobacco use. Am J Med Sci 2003; 326:179.</a></li><li><a class="nounderline abstract_t">Hedin CA, Pindborg JJ, Axéll T. Disappearance of smoker's melanosis after reducing smoking. J Oral Pathol Med 1993; 22:228.</a></li><li><a class="nounderline abstract_t">Maalouf NS, Morand M. Serpentine Supravenous Hyperpigmentation. N Engl J Med 2022; 387:e67.</a></li><li><a class="nounderline abstract_t">Geddes ER, Cohen PR. Antineoplastic agent-associated serpentine supravenous hyperpigmentation: superficial venous system hyperpigmentation following intravenous chemotherapy. South Med J 2010; 103:231.</a></li><li><a class="nounderline abstract_t">Akyurek FT, Sari N, Ugurluoglu C, Kurtipek GS. Serpentine supravenous hyperpigmentation related to carboplatin and vinorelbine chemotherapy: A case report. Dermatol Ther 2019; 32:e12981.</a></li><li><a class="nounderline abstract_t">Khmamouche MR, Debbagh A, Mahfoud T, et al. Flagellate erythema secondary to bleomycin: a new case report and review of the literature. J Drugs Dermatol 2014; 13:983.</a></li><li><a class="nounderline abstract_t">Yamamoto T. Bleomycin and the skin. Br J Dermatol 2006; 155:869.</a></li><li><a class="nounderline abstract_t">Cohen PR. Paclitaxel-associated reticulate hyperpigmentation: Report and review of chemotherapy-induced reticulate hyperpigmentation. World J Clin Cases 2016; 4:390.</a></li><li><a class="nounderline abstract_t">Masson Regnault M, Gadaud N, Boulinguez S, et al. Chemotherapy-Related Reticulate Hyperpigmentation: A Case Series and Review of the Literature. Dermatology 2015; 231:312.</a></li><li><a class="nounderline abstract_t">Khaitan BK, Ahuja R. Erythema Ab Igne. N Engl J Med 2022; 387:e33.</a></li><li><a class="nounderline abstract_t">Beleznay K, Humphrey S, Au S. Erythema ab igne. CMAJ 2010; 182:E228.</a></li><li><a class="nounderline abstract_t">Arnold AW, Itin PH. Laptop computer-induced erythema ab igne in a child and review of the literature. Pediatrics 2010; 126:e1227.</a></li><li><a class="nounderline abstract_t">Adams BB. Heated car seat-induced erythema ab igne. Arch Dermatol 2012; 148:265.</a></li><li><a class="nounderline abstract_t">Duan GY, Stein SL. Erythema ab igne in pediatric patients remote schooling during the COVID-19 pandemic: A case series. Pediatr Dermatol 2021; 38:1361.</a></li><li><a class="nounderline abstract_t">Poddighe D, Assylbekova M, Almukhamedova Z, et al. Pediatric erythema ab igne: clinical aspects and diagnostic issues. Eur J Pediatr 2023; 182:4807.</a></li><li><a class="nounderline abstract_t">Mirgh SP, Shah VD, Sorabjee JS. Perils of Technology - Laptop Induced Erythema Ab Igne (Toasted Skin Syndrome) on Abdomen. Indian J Occup Environ Med 2020; 24:131.</a></li><li><a class="nounderline abstract_t">Nagashima M. Prurigo pigmentosa--clinical observations of our 14 cases. J Dermatol 1978; 5:61.</a></li><li><a class="nounderline abstract_t">Michor-Tscharre C, D'Alì L, Cota C, et al. Clinical and Pathological Spectrum of Prurigo Pigmentosa in Central European Individuals. JAMA Dermatol 2023; 159:864.</a></li><li><a class="nounderline abstract_t">Kim JK, Chung WK, Chang SE, et al. Prurigo pigmentosa: clinicopathological study and analysis of 50 cases in Korea. J Dermatol 2012; 39:891.</a></li><li><a class="nounderline abstract_t">Mufti A, Mirali S, Abduelmula A, et al. Clinical manifestations and treatment outcomes in prurigo pigmentosa (Nagashima disease): A systematic review of the literature. JAAD Int 2021; 3:79.</a></li><li><a class="nounderline abstract_t">Shen A, Cheng CE, Malik R, et al. Prurigo pigmentosa: A multi-institutional retrospective study. J Am Acad Dermatol 2023; 89:376.</a></li><li class="breakAll">Kang S, Lerner EA, Sober AJ, Levine N. Pigmentary disorders from exogenous causes. In: Pigmentation and Pigmentary Disorders, Levine N (Ed), CRC Press, 1993. p.417.</li><li><a class="nounderline abstract_t">Lerner EA, Sober AJ. Chemical and pharmacologic agents that cause hyperpigmentation or hypopigmentation of the skin. Dermatol Clin 1988; 6:327.</a></li><li><a class="nounderline abstract_t">Dai J, Belum VR, Wu S, et al. Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis. J Am Acad Dermatol 2017; 77:902.</a></li><li><a class="nounderline abstract_t">Brandão Neto RA, de Carvalho JF. Diagnosis and classification of Addison's disease (autoimmune adrenalitis). Autoimmun Rev 2014; 13:408.</a></li><li><a class="nounderline abstract_t">Murphy-Chutorian B, Han G, Cohen SR. Dermatologic manifestations of diabetes mellitus: a review. Endocrinol Metab Clin North Am 2013; 42:869.</a></li><li><a class="nounderline abstract_t">Morgan AJ, Schwartz RA. Diabetic dermopathy: A subtle sign with grave implications. J Am Acad Dermatol 2008; 58:447.</a></li><li><a class="nounderline abstract_t">Mishra SK, Gupta N, Goswami R. Plasma adrenocorticotropin (ACTH) values and cortisol response to 250 and 1 microg ACTH stimulation in patients with hyperthyroidism before and after carbimazole therapy: case-control comparative study. J Clin Endocrinol Metab 2007; 92:1693.</a></li><li><a class="nounderline abstract_t">McCullen MA, Crawford DH, Hickman PE. Screening for hemochromatosis. Clin Chim Acta 2002; 315:169.</a></li><li><a class="nounderline abstract_t">Barton JC. Hemochromatosis and iron overload: from bench to clinic. Am J Med Sci 2013; 346:403.</a></li><li><a class="nounderline abstract_t">Santos PC, Krieger JE, Pereira AC. Molecular diagnostic and pathogenesis of hereditary hemochromatosis. Int J Mol Sci 2012; 13:1497.</a></li><li><a class="nounderline abstract_t">Yoshida A, Takahashi K, Tagami H, Akasaka T. Lichen amyloidosis induced on the upper back by long-term friction with a nylon towel. J Dermatol 2009; 36:56.</a></li><li><a class="nounderline abstract_t">Bandhlish A, Aggarwal A, Koranne RV. A clinico-epidemiological study of macular amyloidosis from north India. Indian J Dermatol 2012; 57:269.</a></li><li><a class="nounderline abstract_t">Huilgol SC, Ramnarain N, Carrington P, et al. Cytokeratins in primary cutaneous amyloidosis. Australas J Dermatol 1998; 39:81.</a></li><li class="breakAll">Hurabe K, Nakayama J, Hori Y. Cutaneous amyloidosis. In: The Pigmentary System: Physiology and Pathophysiology, 2nd ed, Nordlund J, Boissy RE, Hearing VJ, et al (Eds), Blackwell Publishing Ltd, 2006. p.924.</li><li><a class="nounderline abstract_t">Qiao J, Fang H, Yao H. Amyloidosis cutis dyschromica. Orphanet J Rare Dis 2012; 7:95.</a></li><li><a class="nounderline abstract_t">Castanedo-Cazares JP, Lepe V, Moncada B. Lichen amyloidosis improved by 0.1% topical tacrolimus. Dermatology 2002; 205:420.</a></li><li><a class="nounderline abstract_t">Carlesimo M, Narcisi A, Orsini D, et al. A case of lichen amyloidosus treated with acitretin. Clin Ter 2011; 162:e59.</a></li><li><a class="nounderline abstract_t">An Q, Zhang L, Zheng S, et al. Thalidomide improves clinical symptoms of primary cutaneous amyloidosis: report of familiar and sporadic cases. Dermatol Ther 2013; 26:263.</a></li><li><a class="nounderline abstract_t">Behr FD, Levine N, Bangert J. Lichen amyloidosis associated with atopic dermatitis: clinical resolution with cyclosporine. Arch Dermatol 2001; 137:553.</a></li><li><a class="nounderline abstract_t">Grimmer J, Weiss T, Weber L, et al. Successful treatment of lichen amyloidosis with combined bath PUVA photochemotherapy and oral acitretin. Clin Exp Dermatol 2007; 32:39.</a></li><li><a class="nounderline abstract_t">Guillet C, Steinmann S, Maul JT, Kolm I. Primary Localized Cutaneous Amyloidosis: A Retrospective Study of an Uncommon Skin Disease in the Largest Tertiary Care Center in Switzerland. Dermatology 2022; 238:579.</a></li><li><a class="nounderline abstract_t">Inamadar AC, Palit A, Sampagavi VV, et al. Cutaneous manifestations of chikungunya fever: observations made during a recent outbreak in south India. Int J Dermatol 2008; 47:154.</a></li><li><a class="nounderline abstract_t">Bandyopadhyay D, Ghosh SK. Mucocutaneous manifestations of Chikungunya fever. Indian J Dermatol 2010; 55:64.</a></li><li><a class="nounderline abstract_t">Riyaz N, Riyaz A, Rahima, et al. Cutaneous manifestations of chikungunya during a recent epidemic in Calicut, north Kerala, south India. Indian J Dermatol Venereol Leprol 2010; 76:671.</a></li><li><a class="nounderline abstract_t">Kandhari R, Khunger N, Singh A. Flagellate pigmentation and exacerbation of melasma following chikungunya fever: a less frequently reported finding. Indian J Dermatol Venereol Leprol 2012; 78:774.</a></li><li><a class="nounderline abstract_t">Dabas G, Vinay K, Mahajan R. Diffuse Hyperpigmentation in Infants During Monsoon Season. JAMA Dermatol 2020; 156:99.</a></li><li><a class="nounderline abstract_t">Sebaratnam DF, Venugopal SS, Frew JW, et al. Diffuse melanosis cutis: a systematic review of the literature. J Am Acad Dermatol 2013; 68:482.</a></li><li><a class="nounderline abstract_t">Piana S, Longo C. Diffuse Melanosis and Melanuria. N Engl J Med 2019; 380:1166.</a></li><li><a class="nounderline abstract_t">Thiem A, Schummer P, Ueberschaar S, et al. Early onset of diffuse melanosis cutis under pembrolizumab therapy illustrates the limitations of anti-PD-1 checkpoint inhibitors. Melanoma Res 2018; 28:465.</a></li><li class="breakAll">Halder RM, Nordlund JJ. Topical treatment of pigmentary disorders. In: The Pigmentary System: Physiology and Pathophysiology, 2nd ed, Nordlund JJ, Boissy RE, Hearing VJ, et al (Eds), Blackwell Publishing Ltd, 2006.</li><li><a class="nounderline abstract_t">Lyons AB, Trullas C, Kohli I, et al. Photoprotection beyond ultraviolet radiation: A review of tinted sunscreens. J Am Acad Dermatol 2021; 84:1393.</a></li></ol></div><div id="topicVersionRevision">Topic 89268 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18189024" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Common dermatologic disorders in skin of color: a comparative practice survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17176298" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Confusions about colour: a classification of discolorations of the skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17176298" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Confusions about colour: a classification of discolorations of the skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24719058" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Dyschromia in skin of color.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22453583" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Top dermatologic conditions in patients of color: an analysis of nationally representative data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28917465" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The impact of skin hyperpigmentation and hyperchromia on quality of life: A cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28917465" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The impact of skin hyperpigmentation and hyperchromia on quality of life: A cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24612852" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The biology of hyperpigmentation syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11807469" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Skin of color: biology, structure, function, and implications for dermatologic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5787098" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Racial differences in the fate of melanosomes in human epidermis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21682796" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Periorbital hyperpigmentation in Asians: an epidemiologic study and a proposed classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31896398" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The physiology of melanin deposition in health and disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35151757" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Disorders of hyperpigmentation. Part I. Pathogenesis and clinical features of common pigmentary disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15887937" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Procedures in primary care dermatology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15798432" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/857837" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Localization of malanin pigmentation in the skin with Wood's lamp.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34235719" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Dermoscopy of acquired pigmentary disorders: a comprehensive review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20497220" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : In vivo reflectance confocal microscopy detects pigmentary changes in melasma at a cellular level resolution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19067964" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Reflectance confocal microscopy for in vivo skin imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19782941" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Reflectance confocal microscopy--state-of-art and research overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19889023" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Reflectance confocal microscopy for pigmentary disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20337829" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Characterization and evaluation of pigment distribution and response to therapy in melasma using in vivo reflectance confocal microscopy: a preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22854540" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Association of melanocortin 1 receptor gene (MC1R) polymorphisms with skin reflectance and freckles in Japanese.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11487574" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The melanocortin-1-receptor gene is the major freckle gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7635560" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21492309" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Laser eradication of pigmented lesions: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27439996" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Partial unilateral lentiginosis is mosaic neurofibromatosis type 1 or not?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34018611" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Partial unilateral lentiginosis: a clinicopathological analysis of 32 cases on the head and neck area in Korea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20633811" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Partial unilateral lentiginosis associated with nevus of Ota.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15539896" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Partial unilateral lentiginosis with ipsilateral Lisch nodules and axillary freckling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22093176" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Low-fluence Q-switched 1,064-nm neodymium-doped yttrium aluminum garnet laser for the treatment of facial partial unilateral lentiginosis in Koreans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23384078" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Partial unilateral lentiginosis treated with alexandrite Q-switched laser: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18201261" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : An observational analysis of erythromelanosis follicularis faciei et colli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21860153" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Facial melanoses: Indian perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22794809" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Topical tacalcitol ointment can be a good therapeutic choice in erythromelanosis follicularis faciei et colli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20584040" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Treatment of erythromelanosis follicularis faciei et colli using a dual-wavelength laser system: a split-face treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26341362" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Idiopathic eruptive macular pigmentation: What is it actually?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8844742" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Idiopathic eruptive macular pigmentation: report of five patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26831572" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Macular pigmentation of uncertain aetiology revisited: two case reports and a proposed algorithm for clinical classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23130237" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Idiopathic eruptive macular pigmentation with papillomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21967469" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Terra firma-forme dermatosis: a retrospective review of 31 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26336622" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Terra firma-forme dermatosis: A report of ten individuals with Duncan's dirty dermatosis and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17511946" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Lichen planus actinicus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18207715" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : [Childhood actinic lichen planus (6 cases)].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14655778" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Lichen planus actinicus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14655778" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Lichen planus actinicus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22309344" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Childhood actinic lichen planus: successful treatment with antimalarials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12046829" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Lichen planus actinicus treated with acitretin and topical corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18005120" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Relapsing lichen actinicus successfully treated with cyclosporin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16631967" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Treatment of solar lentigines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6411778" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The PUVA-induced pigmented macule: a lentiginous proliferation of large, sometimes cytologically atypical, melanocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21790796" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : NB-UVB (311-312 nm)-induced lentigines in patients with mycosis fungoides: a new adverse effect of phototherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23317980" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cutaneous manifestations of gastrointestinal disease: part I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10384348" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : [Cronkhite-Canada syndrome: a new French case].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26216651" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Endoscopic and clinical evaluation of treatment and prognosis of Cronkhite-Canada syndrome: a Japanese nationwide survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26639606" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Early-onset dermatosis papulosa nigra.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8302739" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Dermatosis papulosa nigra in a young child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19845664" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : FGFR3 and PIK3CA mutations in stucco keratosis and dermatosis papulosa nigra.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33852246" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A Systematic Review on the Treatment of Dermatosis Papulosa Nigra.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33017107" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Elective Treatment of Dermatosis Papulosa Nigra: A Review of Treatment Modalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17373158" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Dermatosis papulosis nigra: treatment options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21040130" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Treatment of dermatosis papulosa nigra in 10 patients: a comparison trial of electrodesiccation, pulsed dye laser, and curettage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19469798" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Comparison of electrodesiccation and potassium-titanyl-phosphate laser for treatment of dermatosis papulosa nigra.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26868030" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Carbon dioxide laser ablation of dermatosis papulosa nigra: high satisfaction and few complications in patients with pigmented skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24131098" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Dermatosis Papulosa Nigra and 10,600-nm CO2 laser, a good choice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19796255" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Dermatosis papulosa nigra treatment with fractional photothermolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29864467" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: Results from 2 identical, randomized, double-blind, placebo-controlled, phase 3 studies (A-101-SEBK-301/302).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29864467" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: Results from 2 identical, randomized, double-blind, placebo-controlled, phase 3 studies (A-101-SEBK-301/302).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19469797" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Infraorbital dark circles: definition, causes, and treatment options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23112513" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Idiopathic cutaneous hyperchromia at the orbital region or periorbital hyperpigmentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5797956" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Periorbital hyperpigmentation. An overlooked genetic disorder of pigmentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17921612" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Periorbital melanosis is an extension of pigmentary demarcation line-F on face.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16792642" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Condition known as "dark rings under the eyes" in the Japanese population is a kind of dermal melanocytosis which can be successfully treated by Q-switched ruby laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23344465" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Cutaneous idiopathic hyperchromia of the orbital region (CIHOR): a histopathological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23992162" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Chemical peeling with trichloroacetic acid and lactic acid for infraorbital dark circles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22621220" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Treatment of venous infraorbital dark circles using a long-pulsed 1,064-nm neodymium-doped yttrium aluminum garnet laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21605241" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Treatment of infraorbital dark circles using a low-fluence Q-switched 1,064-nm laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18176232" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Combined therapy using Q-switched ruby laser and bleaching treatment with tretinoin and hydroquinone for periorbital skin hyperpigmentation in Asians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23437990" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Correction of infraorbital dark circles using collagenase-digested fat cell grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23378704" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Dermal Fillers for the Treatment of Tear Trough Deformity: A Review of Anatomy, Treatment Techniques, and their Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24398484" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Calcium hydroxyl-apatite (Radiesse) for the correction of periorbital hollows, dark circles, and lower eyelid bags.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21920241" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Melasma: a comprehensive update: part I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24626644" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Acquired hyperpigmentations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17341870" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Poikiloderma of Civatte: a histopathological and ultrastructural study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22540888" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Histopathologic changes induced by intense pulsed light in the treatment of poikiloderma of Civatte.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18177401" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Treatment of poikiloderma of Civatte using intense pulsed light source: 7 years of experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11335804" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Treatment of poikiloderma of Civatte on the neck with an intense pulsed light source.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10971554" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Treatment of poikiloderma of Civatte with an intense pulsed light source.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30176055" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : A global consensus statement on ashy dermatosis, erythema dyschromicum perstans, lichen planus pigmentosus, idiopathic eruptive macular pigmentation, and Riehl's melanosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15009400" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Erythema dyschromicum perstans: the continuing enigma of Cinderella or ashy dermatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15987286" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Erythema dyschromicum perstans in children: a report of 14 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15987286" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Erythema dyschromicum perstans in children: a report of 14 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1476930" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Erythema dyschromicum perstans in an HIV antibody-positive man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3948533" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Erythema dyschromicum perstans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17116345" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : HLA-DR association with the genetic susceptibility to develop ashy dermatosis in Mexican Mestizo patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17116345" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : HLA-DR association with the genetic susceptibility to develop ashy dermatosis in Mexican Mestizo patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26538750" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Erythema Dyschromicum Perstans: Response to Topical Tacrolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15009398" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Erythema dyschromicum perstans: response to dapsone therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9080892" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Involvement of cell adhesion and activation molecules in the pathogenesis of erythema dyschromicum perstans (ashy dermatitis). The effect of clofazimine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2785092" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Clinical trial with clofazimine for treating erythema dyschromicum perstans. Evaluation of cell-mediated immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26933923" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Erythema Dyschromicum Perstans Response to Isotretinoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30627620" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Erythema dyschromicum perstans: A case report and systematic review of histologic presentation and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14521555" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Erythema dyschromicum perstans in prepubertal children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24365004" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Lichen planus pigmentosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12950331" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : A study of 124 Indian patients with lichen planus pigmentosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33938439" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Lichen Planus Pigmentosus Associated with Topical Olive Oil Application.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33395041" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Oral Lichen Planus Associated With Lichen Planus Pigmentosus and Lichen Sclerosus in Monozygotic Twins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22803712" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Frontal fibrosing alopecia and lichen planus pigmentosus: is there a link?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27233640" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Clinical and dermoscopic features of lichen planus pigmentosus in 37 patients with frontal fibrosing alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19840200" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Clinicopathological characteristics of lichen planus pigmentosus and its response to tacrolimus ointment: an open label, non-randomized, prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21951348" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Linear lichen planus pigmentosus of the forehead treated by neodymium:yttrium-aluminum-garnet laser and topical tacrolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24796489" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : A case of lichen planus pigmentosus that was recalcitrant to topical treatment responding to pigment laser treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31012083" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : A successful combination therapy of tacrolimus, hydroxychloroquine and picosecond laser for lichen planus pigmentosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32875026" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : A case of recalcitrant lichen planus pigmentosus treated by oral isotretinoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7068304" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Riehl's melanosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7068304" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Riehl's melanosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19326022" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Erythrosis pigmentosa mediofacialis: familial occurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10086863" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Erythrosis pigmentosa mediofacialis (Brocq) and erythromelanosis follicularis faciei et colli in the same patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11702317" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Management of facial hyperpigmentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6736340" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Acquired, bilateral nevus of Ota-like macules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19539841" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Acquired bilateral nevus of Ota-like macules (Hori nevus): etiologic and therapeutic considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16403093" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Characteristics of Hori naevus: a prospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16393596" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Treatment of acquired bilateral nevus of ota-like macules (Hori's nevus) with a combination of the 532 nm Q-Switched Nd:YAG laser followed by the 1,064 nm Q-switched Nd:YAG is more effective: prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20415671" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Treatment of acquired bilateral nevus of Ota-like macules (Hori's nevus) using 1064-nm Q-switched Nd:YAG laser with low fluence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10594626" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Q-Switched ruby laser therapy of acquired bilateral nevus of Ota-like macules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10816238" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Treatment of Hori's nevus with the Q-switched Nd:YAG laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12243708" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Clinical use of the Q-switched Nd:YAG laser for the treatment of acquired bilateral nevus of Ota-like macules (ABNOMs) in Koreans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10727320" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Acquired brachial cutaneous dyschromatosis: a common pigmentary disorder of the arm in middle-aged women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22031642" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Acquired brachial cutaneous dyschromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11705248" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Exogenous ochronosis. An update on clinical features, causative agents and treatment options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19061605" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Exogenous ochronosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2923796" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Exogenous ochronosis: an epidemiological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18377596" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Complications of chronic use of skin lightening cosmetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18173595" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Hydroquinone-induced exogenous ochronosis: a report of four cases and usefulness of dermoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2246407" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Hydroquinone-induced localized exogenous ochronosis treated with dermabrasion and CO2 laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23368689" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Effect of combination of 1064 nm Q-switched Nd:YAG and fractional carbon dioxide lasers for treating exogenous ochronosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25837718" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Exogenous ochronosis: a comprehensive review of the diagnosis, epidemiology, causes, and treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25302636" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Erbium-doped yttrium aluminium garnet ablative laser treatment for endogenous ochronosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23464825" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Exogenous ochronosis - successful outcome after treatment with Q-switched Nd:YAG laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15056151" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Treatment of exogenous ochronosis with a Q-switched alexandrite (755 nm) laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26753505" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Melanoma of the Oral Cavity: an Analysis of 46 New Cases with Emphasis on Clinical and Histopathologic Characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22923898" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Laugier-Hunziker syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10568501" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Laugier-Hunziker syndrome: treatment with cryosurgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20012075" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Treatment of Laugier-Hunziker syndrome with the Q-switched alexandrite laser in 22 Chinese patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10343950" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Laugier-Hunziker syndrome: case report and treatment with the Q-switched Nd-Yag laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6961509" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Epidemiologic study of excessive oral melanin pigmentation with special reference to the influence of tobacco habits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17618332" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Smokers' melanosis in a Nigerian population: a preliminary study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14557730" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Oral changes associated with tobacco use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8315602" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Disappearance of smoker's melanosis after reducing smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36546629" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Serpentine Supravenous Hyperpigmentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20134385" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Antineoplastic agent-associated serpentine supravenous hyperpigmentation: superficial venous system hyperpigmentation following intravenous chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31168954" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Serpentine supravenous hyperpigmentation related to carboplatin and vinorelbine chemotherapy: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25116979" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Flagellate erythema secondary to bleomycin: a new case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17034512" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Bleomycin and the skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28035312" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Paclitaxel-associated reticulate hyperpigmentation: Report and review of chemotherapy-induced reticulate hyperpigmentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26422424" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Chemotherapy-Related Reticulate Hyperpigmentation: A Case Series and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36198181" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Erythema Ab Igne.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20159900" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Erythema ab igne.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20921068" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Laptop computer-induced erythema ab igne in a child and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22351838" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Heated car seat-induced erythema ab igne.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34463374" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Erythema ab igne in pediatric patients remote schooling during the COVID-19 pandemic: A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37661206" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Pediatric erythema ab igne: clinical aspects and diagnostic issues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33281387" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Perils of Technology - Laptop Induced Erythema Ab Igne (Toasted Skin Syndrome) on Abdomen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/353107" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Prurigo pigmentosa--clinical observations of our 14 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37436763" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Clinical and Pathological Spectrum of Prurigo Pigmentosa in Central European Individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22901017" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Prurigo pigmentosa: clinicopathological study and analysis of 50 cases in Korea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34409375" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Clinical manifestations and treatment outcomes in prurigo pigmentosa (Nagashima disease): A systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37001731" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Prurigo pigmentosa: A multi-institutional retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37001731" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Prurigo pigmentosa: A multi-institutional retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3288388" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Chemical and pharmacologic agents that cause hyperpigmentation or hypopigmentation of the skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28918974" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24424183" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Diagnosis and classification of Addison's disease (autoimmune adrenalitis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24286954" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Dermatologic manifestations of diabetes mellitus: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18155320" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Diabetic dermopathy: A subtle sign with grave implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17327382" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Plasma adrenocorticotropin (ACTH) values and cortisol response to 250 and 1 microg ACTH stimulation in patients with hyperthyroidism before and after carbimazole therapy: case-control comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11728418" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Screening for hemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24157962" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Hemochromatosis and iron overload: from bench to clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22408404" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Molecular diagnostic and pathogenesis of hereditary hemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19207438" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Lichen amyloidosis induced on the upper back by long-term friction with a nylon towel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22837559" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : A clinico-epidemiological study of macular amyloidosis from north India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9611375" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Cytokeratins in primary cutaneous amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9611375" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Cytokeratins in primary cutaneous amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23234252" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Amyloidosis cutis dyschromica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12444346" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Lichen amyloidosis improved by 0.1% topical tacrolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21533310" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : A case of lichen amyloidosus treated with acitretin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23742287" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Thalidomide improves clinical symptoms of primary cutaneous amyloidosis: report of familiar and sporadic cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11346332" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : Lichen amyloidosis associated with atopic dermatitis: clinical resolution with cyclosporine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17004989" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : Successful treatment of lichen amyloidosis with combined bath PUVA photochemotherapy and oral acitretin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34525472" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : Primary Localized Cutaneous Amyloidosis: A Retrospective Study of an Uncommon Skin Disease in the Largest Tertiary Care Center in Switzerland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18211486" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : Cutaneous manifestations of chikungunya fever: observations made during a recent outbreak in south India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20418982" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : Mucocutaneous manifestations of Chikungunya fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21079311" id="rid191" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>192 : Cutaneous manifestations of chikungunya during a recent epidemic in Calicut, north Kerala, south India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23075658" id="rid192" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>193 : Flagellate pigmentation and exacerbation of melasma following chikungunya fever: a less frequently reported finding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31617869" id="rid193" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>194 : Diffuse Hyperpigmentation in Infants During Monsoon Season.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23219556" id="rid194" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>195 : Diffuse melanosis cutis: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30893538" id="rid195" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>196 : Diffuse Melanosis and Melanuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29781871" id="rid196" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>197 : Early onset of diffuse melanosis cutis under pembrolizumab therapy illustrates the limitations of anti-PD-1 checkpoint inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29781871" id="rid197" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>198 : Early onset of diffuse melanosis cutis under pembrolizumab therapy illustrates the limitations of anti-PD-1 checkpoint inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32335182" id="rid198" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>199 : Photoprotection beyond ultraviolet radiation: A review of tinted sunscreens.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
